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This thesis examined the relationship between stigma 
and factors of psychological wellbeing for individuals 
with neurodegenerative motor conditions.  
Section 1 describes a systematic literature review of 
quantitative correlates of stigma for individuals with 
neurodegenerative conditions, which result in visible 
motor differences. Five electronic databases were 
searched (PsycINFO, Academic Scholar Complete, 
CINAHL, AMED and SCOPUS) on the 17th November 
2017 to identify relevant literature. Free word searches 
relating to stigma and the neurodegenerative conditions 
of Parkinson’s disease (PD), motor neuron 
disease/amyotrophic lateral sclerosis, Huntington’s 
disease and multiple sclerosis were conducted. The 
findings indicate that stigma is related to condition 
severity, psychological factors, and perceptions of 
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health-related quality of life.  Future research should 
statistically examine the role between stigma and 
demographic, social and clinical variables using more 
complex models to determine if bidirectional 
relationships exist.  By furthering our understanding of 
the relationships between stigma and these variables, 
clinical practice can be enhanced at an individual and 
community level.  
Section 2 describes a study examining if the perception 
of control mediates the relationship between stigma and 
health-related quality of life and aspects of psychological 
wellbeing, for individuals with PD. Individuals were 
invited to take part in a survey online, or in a paper 
format on request. Data were then analysed using 
mediational regression models. The findings from this 
sample indicated that control mediates the relationship 
between stigma and health-related quality of life, 
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depression and positive affect. These findings suggest 
that control may be an important factor to consider when 
developing interventions that are designed to reduce 
stigma or increase wellbeing.  
Section 3 presents a critical appraisal of the research 
project, including its development and a detailed 
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Individuals with neurodegenerative conditions that result 
in visible motor differences often experience stigma. The 
aim of this paper was to review systematically correlates 
of stigma for adults with progressive, neurodegenerative 
conditions with a motor component. Parkinson’s 
disease, Huntington’s disease, motor neuron 
disease/amyotrophic lateral sclerosis and multiple 
sclerosis were considered.  
Methods 
Five electronic databases were systematically searched 
to identify relevant studies using free-word searches 




Twenty quantitative research papers were eligible for 
review. Only studies reporting on Parkinson’s disease 
and multiple sclerosis were suitable for inclusion. 
The findings indicate that stigma was related to 
condition severity, psychological wellbeing and 
perceptions of health-related quality of life. The most 
strongly supported finding indicates that higher 
experiences of stigma are associated with increased 
anxiety and depression.  
Conclusions 
Future research should use complex models to examine 
if the relationship between stigma and health-related 
quality of life, and stigma and emotional wellbeing is 
bidirectional. This knowledge may help guide 
intervention delivery and ensure the cost-effective use of 
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psychological resources. For instance, interventions 
which target stigma at a societal level may improve 
psychological wellbeing in those with neurodegenerative 
conditions. Equally, effects of stigma may be considered 
at an individual level by targeting anxiety and depression 
in this population. This in turn may help to improve 
health-related quality of life for these individuals.  
Keywords: stigma, health-related quality of life, 
wellbeing, demographic, neurodegenerative, 
Parkinson’s disease, Huntington’s disease, motor 
neuron disease/amyotrophic lateral sclerosis, multiple 





Stigma and its importance 
Stigma was defined in Goffman’s (1963) seminal work 
as a feeling of being discredited by others for attributes 
that a person possesses. Since then, the concept has 
been researched from various perspectives including 
sociological, anthropological and psychological (Bos, 
Pryor, Reeder & Stutterheim, 2013; Scambler, 2006). 
This has led to the concept being redefined by a number 
of authors in an attempt to incorporate all aspects of the 
process of feeling stigmatized and devalued. For 
example, Link and Phelan (2001, p. 377) argue that 
stigma “exists when elements of labelling, stereotyping, 
separating, status loss and discrimination co-occur in a 
power situation that allows these processes to unfold”; 
thus, the authors acknowledge the relational context in 
which stigma may occur. 
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Both definitions provided above acknowledge the fact 
that individuals may feel a sense of stigma if they 
believe that they have characteristics that are less 
valued than the social norm. A number of characteristics 
may lead an individual to experience stigma. These can 
include ethnicity, gender, disability, sexual orientation 
and presence of illness (Campbell & Deacon, 2006). 
The social context is an important determinant in how 
individuals who possess these characteristics are 
appraised (Crocker & Major, 1989). Individuals who 
have less valued characteristics may experience 
negative reactions from others (Jones, Farina, Hastorf, 
Markus, Miller, & Scott, 1984) such as being treated in a 
derogatory manner, being stared at, questioned, or 
insulted (Rao, Choi, Victorson, Bode, Peterman et al., 
2009). Such direct experiences are known as enacted 
stigma (Scambler, 1989). For individuals who have 
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visible differences, their awareness of discriminatory 
views and negative stereotypes may result in feelings of 
embarrassment, feeling less valued or fearing future 
stigma experiences. Such indirect experiences are 
known as perceived stigma (Scambler, 1989).   
In a condition with a visible component such as epilepsy, 
stigma has been shown to impact on an individual’s 
quality of life and emotional wellbeing (Jacoby, 2002). 
Stigma has been shown to be associated with a number 
of demographic, physiological and psychological 
components for people with epilepsy (Baker, Eccles, & 
Caswell, 2018). For example, experiencing epilepsy at a 
lower age was associated with high reports of stigma 
(Baker et al., 2018). Furthermore, stigma was a 
significant predictor of anxiety and depression for those 
with this condition (Baker et al., 2018). This previous 
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review therefore indicates the impact of stigma for 
individuals experiencing a visible health condition. 
Experiencing stigma (perceived or enacted) may result 
in an individual isolating themselves or feeling excluded 
(Maffoni, Giardini, Pierobon, Ferrazzoli & Frazzitta, 
2017). Withdrawal may lead to a loss of meaningful 
activity and sense of personal identity. This may 
increase negative affect, depression and anxiety 
(Simpson, McMillan, & Reeve, 2013). The impact of 
stigma goes beyond the individual and its effects can be 
felt at a systemic level, affecting intimate and wider 
social relationships (Laryea & Gien,1993). 
Stigma experience also impacts interpersonal 
relationships within the health care system 
(Hatzenbuehler, Phelan & Link, 2013). Experiencing 
stigma from health care professionals is associated with 
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the anticipation of future stigma experiences (Earnshaw 
& Quinn, 2012). Individuals who anticipate stigma may 
be less likely to seek support from healthcare services 
which may result in poor health outcomes (Earnshaw et 
al., 2012). 
Stigma and visible health conditions  
It has been suggested that individuals who possess 
characteristics that are less valued and which are highly 
visible, experience a greater level of stigma than those 
whose differences are less overtly identifiable (Joachim 
& Acorn, 2000; Goffman, 1963). 
For individuals with health conditions with visible 
differences, a number of factors have been suggested 
which impact social relationships through stigma (Jones 
et al.,1984). From an evolutionary perspective, 
appearance indicates a degree of ‘fitness’ or 
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acceptability. When a person differs from the social 
norm, they may be considered less acceptable. If a 
person with a health condition has visible signs of 
difference, they may wish to conceal these in order to 
appear more in line with the social norm. When an 
individual has a sense of control over the visibility of 
their condition, they may experience less stigma (Jones 
et al., 1984). For individuals with progressive conditions, 
controllability and concealability decreases over time. As 
symptoms progress, conditions may become more 
visible and stigma experiences may increase (Jones et 
al., 1984).  
Stigma and neurodegenerative conditions 
While people with a wide range of health conditions can 
experience stigma, it is especially relevant in people with 
neurodegenerative conditions. For example, Parkinson’s 
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disease (PD), Huntington’s disease (HD), motor neuron 
disease (MND)/amyotrophic lateral sclerosis (ALS) and 
multiple sclerosis (MS) often produce visible symptoms, 
such as tremor, jolting, uncontrolled movements and 
speech difficulties. These neurodegenerative conditions 
are incurable and are likely to progress unpredictably 
(Rao et al., 2009). Moreover, they can affect all types of 
movement, from gross to fine motor skills, facial 
expressions, speech production and eating (Tickle-
Degnen & Lyons, 2004). 
Individuals with these neurological conditions may find 
everyday tasks more difficult and may require aids or 
assistance from others. The resulting visible differences 
is related to the experience of stigma for individuals with 
PD (Ma, Saint-Hilaire, Thomas & Tickle-Degnen, 2016), 
MND/ALS (Hugel, Grundy, Rigby & Young, 2006), HD 
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(Pringsheim et al., 2012) and MS (Grytten & Måseide, 
2006).   
Justification of this review 
Previous reviews have examined the effects of stigma in 
a number of health conditions such as: HIV, (Holzemer 
et al., 2009) epilepsy, (Baker et al., 2018; Jacoby, 2002) 
and dementia (Bunn et al., 2012). 
This will be the first known review to explore the 
correlates of stigma for progressive neurodegenerative 
conditions with a motor component e.g. PD, HD, MS and 
ALS/MND.  
There is growing research exploring the correlates of 
stigma in the aforementioned conditions. Demographic 
factors such as age have been shown to be related to 
stigma (Carod-Artal, Vargas & Martínez-Martin, 2007).  
A previous study has also found stigma experience to be 
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associated with condition severity (Cano-de-la-Cuerda, 
Vela-Desojo, Miangolarra-Page, Macías-Macías, 
Muňoz-Hellín, 2011). Therefore, stigma and its 
relationship to unmodifiable variables such as age, 
gender and condition severity were examined in this 
review. 
A number of studies have found a relationship between 
high reports of stigma and reduced psychological 
wellbeing, measured using anxiety and depression 
scales, in PD and MS (Valvano et al., 2016; Martínez-
Martín, Serrano-Dueñas, Vaca-Bquero, 2005).  Stigma 
was found to be a significant predicator of health-related 
quality of life (HRQoL) in a study by Valvano for 
individuals with MS (Valvano et al., 2016). 
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Systematically reviewing the literature will allow for a 
greater understanding of the relationships between 
stigma and demographic, clinical and HRQoL factors.  
This will further the understanding of the correlates and 
predictors of psychosocial outcomes for individuals with 
neurodegenerative conditions with a visible, motor 
component.  These results may help to inform effective 
intervention strategies that aim to reduce the prevalence 
of stigma and its effect on these individuals.  
In summary, this paper aimed to review systematically 
quantitative research exploring the correlates and 
predictors of stigma for individuals with such 





Relevant studies were identified for review through a 
systematic search of five electronic databases in 
November 2017: PsycINFO, Academic Search 
Complete (ASC), Cumulative Index to Nursing & Allied 
Health Literature (CINAHL), Allied & Complementary 
Medicine Database (AMED) and SCOPUS.  The 
databases were selected in consultation with an 
academic librarian for their focus on psychological, 
sociological and medical studies. Focused search terms 
were generated based on the review question and 
consisted of “stigma”, “Parkinson’s disease”, “motor 
neuron disease”, “amyotrophic lateral sclerosis”, 
“Huntington’s disease” and “multiple sclerosis”. A broad 
search strategy using a free text search was used to 
ensure that all relevant literature was captured. The 
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subject librarian was consulted regarding this search 
process and confirmed that this strategy would produce 
the most comprehensive search of the literature. 
“Stigma” was not expanded with the truncation symbol 
to include broader terms such as “stigmatized” or 
“stigmatising” due to the specific nature of this review. 
The searches were restricted to peer-reviewed literature 
and the English language.  Duplicates were removed 
and the titles and abstracts of the remaining papers 
were then screened to determine suitability for this 
review using the title, abstract or full text, excluding 
articles according to research design, methodology and 
sample population. Handsearching was carried out on 
included papers and a Google Scholar search was 
conducted to ensure inclusion of all relevant articles. Full 
text articles were assessed and included if a correlation 
or regression of stigma (scale or subscale) was present 
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against demographic, social or clinical factors.  A paper 
by Maffoni et al., (2017) was excluded due to its 
qualitative research design, although stigma and its 
associated relationships were reviewed in the study. 
This process was carried out by the author. The 
following inclusion criteria were applied and papers that 
did not meet these were removed: 
• Studies used quantitative methodology. 
• Studies including participants who had a diagnosis 
of PD, MND/ALS, HD or MS. 
• Studies including a measure of stigma (scale or 
subscale) that was correlated with demographic, 
social or clinical factors. 
The exclusion criteria consisted of:  
• Studies using qualitative designs.  
• Intervention studies. 
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• Studies where stigma was measured but not 
correlated with demographic, social or clinical 
factors. 
• Studies that focused on individuals with the HD 
gene but at the pre-symptomatic phase as at this 
point there would be no easily discernible physical 
difference.  
• Non-English papers. 
Appraisal of methodological quality 
All twenty studies were cross-sectional in design. A 
design-appropriate National Institute for Clinical 
Excellence (NICE) recommended quality appraisal tool 
was used (see Appendix A): The ‘Graphical appraisal 
tool for epidemiological studies’ (GATE; Jackson et al., 
2006). An appraisal form derived from this tool was used 
to evaluate the study in four areas, including population 
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(e.g. “Was the method of selection of participants from 
the eligible population well described?”), method of 
selection of exposure (e.g. “How was selection bias 
minimised?”), study outcome (e.g. “Were the outcome 
measures and procedures reliable?”) and statistical 
analyses (e.g. “Was the study sufficiently powered to 
detect an intervention effect if one exists?”; Jackson et 
al., 2006). Methodological quality was assessed and 
given one of five ratings: ‘++’ (the study has been 
designed to minimize bias); ‘+’ (the study may not have 
addressed all potential sources of bias); ‘–’ (significant 
sources of bias may be present); ‘NR’ (not-reported); 
‘NA’ (not-applicable; Jackson et al., 2006).   
Results 
The search produced a total of 580 papers including 
duplicates. Handsearching of relevant papers and 
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searching using Google Scholar identified 3 further 
studies. Therefore, a total of 583 papers were collated 
for review. After duplicates were removed, 295 papers 
were screened using the title and abstract in line with 
the inclusion criteria. If stigma was not mentioned as a 
correlate or predictor of another variable records were 
removed, leaving 87 articles which were screened using 
the full-text, again in line with the inclusion criteria. 
Twenty studies met the inclusion criteria, and 
justifications for exclusion of preliminary identified 
































87 full-text articles 
assessed for eligibility 
295 records screened 
on title/abstract  
 
20 studies included for 
review  
Search strategy 
“Parkinson’s disease”, OR 
“Huntington’s disease” OR 
“motor neuron disease” OR 
“amyotrophic lateral 
sclerosis” OR “multiple 
sclerosis” AND “stigma” 
 
 288 duplicates removed 
 
208 records removed as 
stigma not a correlate/ 
predictor of another variable  
 
67 records were excluded on 
the following grounds:  
Qualitative: 13 




Focus not on psychology: 4 
Intervention study: 13 










An overall review of the included studies can be seen in 
Table 1 which includes key features of each study’s 
sample, design, measures used and overall findings, 




























Summary of results 





































stigma and: total self-
efficacy scores (r =    
-.29), control 
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.04); at 60 
extensions (r = .09) 





























correlated with the 
following factors: 
SCOPA-MS I (r = 
.23), SCOPA-MS III 
(r = .22) SCOPA 
TOTAL (r = .23), CISI 
PD (r = .28), HADS-A 
(r = .41), HADS-D (r 
= .32), SCOPA PS-SI 
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stigma and the 
following variables: 
male CD (r = .24), 
male DS (r = .29), 
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factors: SCOPA-AUT 
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UPDRS IV (r = .44), 
dyskinesia (r = .41), 
FSS (r = .36), motor 
scores (r = .37), 
gastrointestinal 
function (r = .25), 
urinary function (r = 
.28), cardiovascular 
function (r = .21), 
PSQI (r = .26), ESS 
(r = .30), SCOPA 
sleep (night; r = .34), 
SCOPA sleep (day; r 
= .29), PPRS (r = 
.26), HDRS (r = .33), 
HADS–A (r = .31), 
HADS-D (r = .33), 
FSS (r = .36), PVAS 







































(β = 12.6). Stigma 
predicted QoL for 































































found between the 
stigma dimension of 


















36 dimensions of 
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= -.30), and mental 
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Stigma was a 
significant negative 
predictor of quality of 
life for individuals in a 
rural life setting 
(compared to urban 
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UPDRS III (r = .33), 
PD ADLS (r = .32), H 
& Y (r = .30), 
Depression (r = .48), 
Anxiety (r = .29), 
Stress (r = .36), 
Optimism (r = -.32), 





































stigma and age (β = -
.30), and stigma and 
the following items 
from the UPDRS I: 
apathy (β = .17), 
depression (β = .23), 
and urinary problems 
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fusion (r = .41), 
depression (r = .39), 
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Stigma was a 
significant predictor 
of depression (β = 
.11) and HRQoL (β = 




stigma and: anxiety 
(β = .22), depression 
(β = .11) and HRQoL 
(β = .14). Depression 
(β = .21), anxiety (β = 




between stigma and 










































was a significant 
predictor of motor 
scores (β = 1.03) and 
CD (β = 1.12).  
In multiple linear 
regression, stigma 
significantly predicted 
CD (β = 1.11).  
 
Note: CD: Condition Duration; DS: Disease Severity; NR: Not reported; n.s. Non-
significant; CIRS-G: Cumulative Illness Rating Scale- Geriatrics; CISI PD: Clinical 
Impression of Severity Index for Parkinson’s Disease; GDS: Geriatric Depression 
Scale; EQ-5D: EuroQuol-five domain questionnaire, five level response version; EQ-
VAS: EuroQuol Visual Analog Scale; ESS: Epworth Sleepiness Scale; FSS: Fatigue 
Severity Scale; GDS: Geriatric Depression Scale; H & Y Scale: Hoehn and Yahr Scale; 
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HADS-A: Hospital Anxiety and Depression Scale- Anxiety; HADS-D: Hospital Anxiety 
and Depression Scale – Depression; HDRS: Hamilton Depression rating scale; ICRD: 
Impulse Control and Related Disorders; LECD: Levodopa equivalent drug dose; MDS: 
Movement Disorder Society; PD ADLS: Parkinson’s Disease -Activities of Daily Living 
Scale; PSQI: Pittsburgh Sleep Quality Index; PVAS: Pain Visual Analogue Scale; S&E: 
Schwab & England Scale; Activities of Daily Living Scale; SCOPA PS-SI, SCOPA-MS I, 
SCOPA-MS III, SCOPA TOTAL, SCOPA-AUT Thermoregulatory Total - Scales for 
Outcomes for Individual’s with Parkinson’s Disease; SF-36: The Short Form (36) Health 
Survey; SEQ: The Self-Efficacy Questionnaire; UPDRS: The Unified Parkinson’s 
Disease Rating Scale; UPDRS Part I: Non-motor symptoms of daily living; UPDRS Part 
II: Motor symptoms of daily living; UPDRS Part III: Motor examination; UPDRS Part IV: 
Complications of therapy 
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The total number of participants across all 20 studies 
was 2,928. This included 2,553 individuals with PD (87% 
across 16 studies) and 375 individuals with MS (13% 
across 4 studies). No results were found for HD and 
MND/ALS populations. The average number of 
participants per study was 52.  
Only five studies reported an age range; using these 
studies, an age range of 22-92 years was present. All 
studies reported a mean age. A weighted mean age for 
the total number of participants within each study was 
calculated for the PD studies (weighted mean = 66 
years) and MS studies (weighted mean = 45 years). 
Studies were conducted worldwide and included 
Europe, North and South America, Asia and Australia 
(see Table 1 for details). Three studies were conducted 
in the UK. One study was carried out across five 
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European countries, including the UK, France, 
Germany, Italy and Spain. Of ten studies, two were 
carried out in each of the following countries: Spain, 
Brazil, Slovakia, Singapore and USA. The remaining 
countries included Norway, Croatia, Portugal, Canada, 
Australia and Taiwan, of which, one study was 
conducted in each country. All of the studies were of 
cross-sectional design, with 14 employing regression 
analyses and 6 implementing purely correlational 
analyses. 
Study Measures 
A total of five different measures of stigma were used 
across the 20 included studies (see Table 1 for details). 
Fifteen studies used the well-validated PDQ-39 scale 
(Jenkinson, Fitzpatrick, Peto, Greenhall & Hyman, 1997) 
to measure stigma in PD; in this general HRQoL scale, 
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stigma is measured using a thirty-nine-item subscale. 
One study used a single item from the PDQ-8 
(Jenkinson & Fitzpatrick, 2007) and another study used 
the Self Efficacy Questionnaire (Tedman, Thornton, & 
Baker 1995) for MS. One study used the Attitudes of 
Others Scale, adapted from the Explanatory Model 
Interview Catalogue (Weiss et al., 1992) and the Pain 
Stigma Scale (Lennon, Link, Marbach & Dohrenwend, 
1989).  Lastly, two studies used the nine-item Stigma 
Scale (Reece, 2003), adapted for MS. 
Summary of quality appraisal 
An overview of the methodological quality of the papers 
used in this review is included in Table 2.  
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Table 2. Quality Appraisal  
Study Population Method of 
selection of 
exposure 
Outcomes Analyses Overall 
Rating 
Airlie et al., 
2001 
1.1: ++ 
1.2: +  
1.3: + 
Overall: + 
2.1: –, –    
2.2: ++  
2.3: NA 
2.4: NR  
2.5: ++ 
Overall: + 
3.1: –   
3.2: + 
3.3: NA  
3.4: NA 
3.5: NA 
Overall: –    
4.1: NR  
4.2: NR, +  
4.3: ++ 







1.1: –, + 
1.2: +, +, –   
1.3 –, NR, + 
Overall: –    
2.1: NR, NR 
2.2: +, +,  
2.3: NA, NA, 
NA 
3.1: NR, +, NR, 
+ 3.2: ++, ++ 
3.3: +, NA, NA 
3.4: NA, NA, NA 
4.1: NR, NR, 
NR 
4.2: ++, –,    





2.4: NR, –, –  
2.5: +, + 
Overall: + 
3.5: NA, NA, NA 
Overall: + 




et al., 2008 
1,1: ++, + 
1.2: –, ++, – 
1.3: –, ++, – 
Overall: – 
2.1 NR  
2.2 + 
2.3 NA 
2.4 NR, ++, 
++ 
2.5 NR, + 
Overall: + 
3.1: NR, –, NR, 
+ 
3.2: –, ++  
3.3: ++, NA, NA 
3.4: NA, NA, NA 
3.5: NA, NA, NA  
Overall: NA 
4.1: NR, NA, 
NR 
4.2: ++, ++  
4.3: ++, NR  






et al., 2007 
1.1: ++, +  
1.2: – –, +, – 
–   
1.3: NR, ++, 
NR, – – 
2.1: – – 
2.2: ++, ++ 
2.3: NA, NA 
3.1: NR, – –, 
NR, +, + 
3.2: ++, ++ 
3.3: ++, NA, NA 
4.1: NR, +  
4.2: ++, + 
4.3: ++, NR 





Overall: – 2.4: NR, – –, 
– – 
2.5: NR, + 
Overall: + 
 
3.4: NA, NA, NA 





1.1: ++, –   
1.2: NR, +, 
++ 
1.3: –, +, 
++, ++ 
Overall: + 
2.1: NR, NR 
2.2: ++, ++ 
2.3: NA, NA, 
NA 
2.4 ++, –, –   
2.5: –, NR 
Overall: + 
3.1: NR, –, + 
3.2: ++, ++ 
3.3: +, NA, NA 
3.4: NA, NA, NA 
3.5: NA, NA, NA 
Overall: + 
4.1: NR, NR, 
NR 
4.2: ++, - 
4.3: ++, NA 







1.1: – –, – – 
1.2: – –, – –, 
– – 
2.1: NR, NR 
2.2: ++, ++  
2.3: NA, NA 
3.1: NR, +, NR, 
NR 
3.2: ++ 
4.1: NR, NR 
4.2: ++, + 





1.3: NR, – –, 





2.4: – –, – –, 
– – 
2.5: ++, ++ 
Overall: ++ 
3.3: ++, NA, NA 
3.4: NA, NA, NA 
3.5: NA, NA, NA 
Overall: + 







1.2: ++  
1.3: ++  
Overall: ++ 
2.1: NR   
2.2: ++ 
2.3: NA 
2.4: -  
2.5: ++  
Overall: +  
3.1: ++, –   
3.2: NA  
3.3: NA  
3.4: NA  
3.5: NA  
Overall: + 
4.1: –     
4.2: +  
4.3: +   






1.1: +, + 2.1: NR, NR  
2.2: ++, ++ 
3.1: +, –, –, – 
3.2: ++, ++ 
4.1: –, –  





1.2: NR, ++, 
+ 1.3: –, ++, 
+, ++ 
Overall: – 
2.3: NA, NA, 
NA 
2.4: +, –, –  
2.5: NR, NR 
Overall: + 
 
3.3: –, NA 
3.4: NA, NA, NA 
Overall: – 
 
4.3: ++, –  






1.1: +, +  
1.2: +, ++, 
NR  
1.3: NR, ++,    
NR, + 
Overall: + 
2.1: NR, NR  
2.2: ++, ++  
2.3: NA, NA, 
NA 
2.4: NR 
2.5: NR, –, –   
Overall: + 
 
3.1: ++, –, +, ++  
3.2: ++, ++  
3.3: NA, NA, NA 
3.4: NA, NA, NA 
3.5: NA, NA, NA 
Overall: NA 
4.1: NR, +  
4.2: ++, –   
4.3: ++, NR 










1.1: ++, ++ 
1.2: NR, ++, 
NR 
1.3: ++, ++, 
– 
Overall: – 
2.1: NR, NR 
2.2: –, – 
2.3: NA, NA, 
NA 




3.1: NR, –, + 
3.2: ++, ++ 
3.3: ++, NA, NA 
3.4: NA, NA, NA 
3.5: NA, NA, NA 
Overall: + 
4.1: NR, NR, 
NR 
4.2: ++, – 
4.3: ++, NR 








1.1: ++, ++ 
1.2: – 




2.2: ++, ++ 
2.3: NA, ++, 
NA 
2.4: ++, ++, 
NA 
2.5: NR 
3.1: ++, –, +, – 
3.2: ++, ++ 
3.3: ++, NA, NA  
3.4: NA, NA, NA 
3.5: NA, NA, NA 
Overall: +  
4.1: NR, NR 
4.2: ++ 
4.3: ++, ++ 










Luo et al., 
2005 
1.1: + 
1.2: NR, +  
1.3: NR, +, 
++ 
Overall: + 
2.1: NR, NR 
2.2: +, ++ 
2.3: NA, NA, 
NA 
2.4: NR, –, – 
2.5: NR, + 
Overall: + 
3.1: ++, –, +, ++ 
3.2 ++, +  
3.3 ++, NA, NA 
3.4: NA, NA, NA 
3.5: NA, NA, NA 
Overall: ++ 
4.1: NR, NA, 
NR  
4.2: ++, –  
4.3: ++, – 








Martín et al., 
2005 
1.1: –, NR  
1.2: +, –  
2.1: –, –  
2.2: ++, ++ 
3.1: ++, –, +, ++  
3.2: ++, ++  
3.3: +, NA, NA 
4.1: NR, NA, 
NA 





1.3: NR, –, 
NR, –   
Overall: – 
2.3: NA, NA, 
NA 
2.4: NR, –, –   
2.5: NR, –   
Overall: – 
 
3.4: NA, NA, NA 
3.5: NA, NA, NA 
Overall: + 
4.3: ++, –   





1.1: ++  
1.2: +  














4.1: NR  
4.2: ++   
4.3: ++ 




Phu et al., 
2014 
1.1: – –, – – 
1.2: ++, ++, 
– –  
2.1: NR, NR 
2.2: ++, +  
3.1: NR, +, NR, 
NR 
3.2: ++, +  
4.1: –, – – 





1.3: NR, ++, 
NR, ++ 
Overall: +  
2.3: NA, NA, 
NA 
2.4: ++, – –, 
– – 
2.5: NR, +  
Overall: + 
 
3.3: +, NA, NA 
3.4: NA, NA, NA 
3.5: NA, NA, NA 
Overall: + 
4.3: ++, ++ 





1.1: +, + 
1.2: ++, ++, 
++ 




2.1: NR, NR 
2.2: ++, ++  
2.3: NA, NA 
2.4: NR, +, + 




3.1: ++, – –, ++, 
++  
3.2: ++, ++ 
3.3: ++, NA, NA 
3.4: NA, NA, NA 
3.5: NA, NA, NA 
Overall: ++ 
4.1: ++, NR 
4.2: ++, +  
4.3: ++, NR 








et al., 2015 
1.1: –, NR 
1.2: ++, – –, 
++ 
1.3: ++, ++, 
NR, ++ 
Overall: + 
2.1: NR, NR 
2.2: ++, ++,  
2.3: NA, NA, 
NA 
2.4: ++, – –, 
– – 
2.5: NR, – – 
Overall: ++ 
3.1: ++, – –, +, 
++  
3.2: ++, ++  
3.3: ++, NA, NA 
3.4: NA, NA, NA 
3.5: NA, NA, NA 
Overall: ++ 
4.1: NR, NR 
4.2: NR, – – 
4.3: ++, ++ 







Tu et al. 
2017 
1.1: +, – – 
1.2: +, ++, 
NR 
1.3: +, +, 
NR, ++  
Overall: + 
2.1: +  
2.2: ++, ++ 
2.3: NA, NA, 
NA 
2.4: NR, – –, 
– – 
Overall: + 
3.1: ++, – –, 
NR, ++ 
3.2: ++, ++ 
3.3: ++, NA, NA 
3.4: NA, NA, NA 
3.5: NA, NA, NA 
Overall: ++ 
4.1: NR, NR 
4.2: ++, – – 
4.3: ++, NR  









1.1: ++, ++ 
1.2: +  
1.3: +  
Overall: + 
2.1: NR  





3.1: ++, –, –, 
NR 
3.2 NR, +  
3.3 +, NA, NA 
3.4 NA, NA, NA 
3.5 NA, NA, NA 
Overall: + 
4.1: NR, NR, 
++  
4.2: ++, + 
4.3: ++, NR 






Zhao et al., 
2008   
1.1: ++, ++ 
1.2: ++, ++, 
+ 
1.3: +, +, +, 
++ 
Overall: ++ 
2.1: NR, NR 
2.2: ++, + 
2.3: NA, NA, 
NA 
2.4: NR, –, –   
2.5: ++  
Overall: + 
3.1: NR, +, NR, 
+ 
3.2 ++, ++ 
3.3 ++, NA, NA 
3.4 NA, NA, NA 
3.5 NA, NA, NA 
Overall: ++ 
4.1 NR, NR, 
NR 
4.2 +, –,   
4.3 ++, NA 






Note: EV: external validity; IV: internal validity; NA: not applicable; NR: not reported; ++: 
all or most of the checklist criteria have been fulfilled; + Some of the checklist criteria 
have been fulfilled; – Few or no checklist criteria have been fulfilled. 
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Overall, of the included studies in this review, 19 were 
rated satisfactory in terms of their overall quality. Only 
one study was rated as having potential sources of bias 
for both internal and external validity (Herlofson & 
Larson, 2003).  However, the results of this study did not 
differ from that of other included papers and therefore 
was included as part of the review. 
The extent to which the findings of the papers can be 
generalized to a wider population should be considered 
with some caution as only two of the studies received 
the highest rating of external validity (Hechtner et al., 
2014; Simpson et al., 2014), with a further seven studies 
receiving satisfactory ratings (Jesus-Ribeiro et al., 2017; 
Penwell-Waines et al., 2017; Tu et al., 2017; Valvano et 
al., 2016; Phu et al., 2014; Skorvanek et al., 2015; Airlie 
et al. 2001). Inclusion criteria were narrow and restricted 
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to PD populations of mild to moderate severity, which 
limit the generalisability of the findings. Some studies 
reported narrow sample parameters excluding, for 
example, individuals who used walking aids (Cano-de-
la-Cuerda et al., 2011), had sensory impairments 
(Martínez-Martín et al., 2005), or may have been 
illiterate (Klepac et al., 2007; Martínez-Martín et al., 
2005).  
The validity and reliability of measures was referenced 
in the majority of studies, however, supporting evidence, 
including Cronbach’s alpha, was not consistently 
reported.  
Only one of the included studies reported a prospective 
power calculation (Simpson et al., 2014), however two 
studies did comment on sample size limitations and 
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implications for findings (Herlofson et al., 2003; Phu et 
al., 2014).   
Main findings  
The findings of the study will be considered in terms of 
stigma’s relationship with four broad factors; 
demographic, condition severity, psychological and 
HRQoL. 
Demographics 
Seven of the included studies examined the relationship 
between stigma and demographic factors such as age, 
gender and ethnicity (Skorvanek et al., 2015; Hechtner 
et al., 2014; Simpson et al., 2014; Dubayova et al., 
2009; Zhao et al., 2008; Carod-Artal et al., 2007; Klepac 
et al., 2007). 
While generally age might be considered to be a factor 
that correlates with stigma experience (Goffman, 1963; 
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Tiggemann & Lynch, 2001), with younger individuals 
reporting higher levels of stigma, the findings of this 
review vary as to whether age has an association with 
stigma. Carod-Artal et al. (2007) report a weak negative 
association between age and stigma for individuals with 
PD (r = -.20), with younger individuals experiencing 
higher levels of stigma. Skorvanek et al. (2015) found 
age to be a significant predictor of stigma when entered 
into a regression model (β = - .30), again with younger 
individuals reporting higher levels of stigma. A further 
PD study, Dubayova et al. (2009) found a small 
association for age and stigma for females of a younger 
age only (r = -.22). Non-significant findings between age 
and stigma were also reported (Simpson et al., 2014; 
Zhao et al., 2008). 
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The effect of gender on stigma experience was not 
found in this review. Three studies report no effect 
between gender and stigma experience (Skorvanek et 
al, 2015; Simpson et al., 2014; Zhao et al., 2008) and 
only one study reports a significant correlation 
(Dubayova et al., 2009). Dubayova et al. (2009) found 
an effect of gender in the relationship between 
personality type and stigma, with neuroticism and stigma 
correlating at a moderate effect size for women only (r = 
.30). However, it accounted for only a small proportion of 
the variance within the regression model when 
controlling for age, functional status and condition 
duration (adjusted R2 =.07).  
Other papers have examined the relationship between 
stigma and additional demographic factors such as 
ethnicity, marital status, work status, employment type, 
72 
 
years since diagnosis, years since symptom onset; 
which were all found to be non-significant (see Table 1). 
The study by Klepac et al. (2007) identified living 
environment to be a significant predictor of stigma 
experience, with individuals living in rural settings 
reporting greater levels of stigma than urban residents. 
In summary, when considering demographic variables, 
the review found mixed findings for the relationship 
between stigma and age. Stigma was not found to 
correlate with any other demographic variables.  
Condition severity 
It is argued that visibility plays a role in stigma 
experience (Jones et al., 1984) and as conditions 
progress reported stigma experience may increase.  
Stigma and condition severity was found to be positively 
related in eight of the reviewed studies (Tu et al., 2017; 
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Hechtner et.al, 2014; Simpson et al., 2014; Cano-de-la-
Cuerdo et al., 2011; Gallagher et al., 2010; Carod-Artal 
et al., 2008; Luo et al., 2005; Martínez-Martín et al., 
2005). Higher stigma scores were associated with 
poorer autonomic functioning in two studies (Skorvanek 
et al., 2015; Gallagher et al., 2010). Two studies report a 
significant relationship between stigma and dyskinesia 
(involuntary movements), (Hechtner et.al, 2014; 
Gallagher et al. 2010). As individuals’ physical 
symptoms increased, the higher the reported 
experiences of stigma. Gallagher et al. (2010) reported a 
correlation between dyskinesia and stigma at a medium 
effect size (r =.41). Hechtner et al. (2014) reported 
dyskinesia to be a significant predictor of stigma. 
Movement difficulties and their relationship to stigma 
was examined in a number of studies (Tu et al., 2017; 
Skorvanek et al., 2015; Simpson et al., 2014; Cano-de-
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la-Cuerda et al., 2011; Carod-Artal et al., 2008; Zhao et 
al., 2008; Martínez-Martín et al., 2005). Physiological 
decline was positively related to stigma experience in 
the studies by Cano-de-la-Cueda et al. (2011) and Luo 
et al. (2005). Cano-de-la-Cueda et al. (2011) found that 
physical restriction of movement significantly correlated 
with stigma at a medium effect size (r= .45). Luo et al. 
(2005) reported that high stigma experiences were 
related to poor physical mobility. The study by Simpson 
et al. (2014) also reports a significant relationship 
between motor functioning and stigma (r= .3), with a 
small-moderate effect size. In the same study, the stage 
of the condition correlated with stigma experience (r = 
.3). This study achieved the highest rating of ecological 
validity due to the inclusion of individuals spanning the 
condition trajectory. This contrasts with two studies 
which examined the relationship between the stage of 
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condition and stigma experience, and found no effect 
(Carod-Artal et al., 2008; Martínez-Martín et al., 2005). 
Physician-rated motor impairments did not correlate with 
stigma experience in two studies (Tu et al., 2017; 
Martínez-Martín et al., 2005).   
With increasing duration in progressive 
neurodegenerative conditions, visible signs of difference 
become more apparent over time. Findings suggest that 
condition duration is not related to stigma experience as 
two studies reported a non-significant finding for this 
relationship (Skorvanek et al., 2015; Simpson et al., 
2014). With an increase in condition duration, comes an 
increase in age and a higher likelihood of experiencing 
illness (Bury, 1982). Perceptions of stigma may be less 
likely to increase in later life if having a condition is 
regarded typical for an individual based on age (Bury, 
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1982). However, two studies report a relationship 
between stigma and condition duration (Dubayova et al., 
2009; Zhao et al., 2008). The Dubayova et al. (2009) 
study examined this relationship and found a significant 
correlation for condition duration (r = .29) and condition 
severity (r = .24) for males only when controlling for age, 
functional status and disease (Dubayova et al.; 2009). 
Zhao et al. (2008) reported PD duration to be a 
significant predictor of stigma. This study however did 
not provide details on any of the factors in the model 
which were controlled, and only individuals with mild PD 
were included. It is therefore possible that such a 
relationship exists only for those with less visible 
symptoms. It is important to note that the Zhao et al. 
(2008) study received an overall less than satisfactory 
rating of ecological validity. Studies that received higher 
scores of methodological rigor and generalisability did 
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not replicate the finding that stigma predicts condition 
duration (Skorvanek et al., 2015; Simpson et al., 2014).  
Levadopa use and stigma experience is reported in one 
study by Phu et al. (2014) and a non-significant 
association was reported.   
In summary, studies suggest that increasing 
physiological decline (i.e. increasing condition severity) 
is associated with higher stigma experience. There 
appears to be little consistency in the findings in the 
relationship between stigma experience and condition 
duration. 
Psychological factors  
More than half of the included papers report 
associations between stigma and psychological factors.  
Nine studies found a significant correlation between 
stigma and depression (effect sizes ranged from small to 
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moderate, with higher stigma scores related to higher 
depression scores; Jesus-Ribeiro et al., 2017; Tu et al., 
2017; Valvano et al., 2016; Simpson et al., 2014; 
Gallagher et al, 2010; Carod-Artal et al., 2008; Luo et al, 
2005; Martínez-Martín et al., 2005; Looper and 
Kirmayer., 2004). Stigma was also found to be a 
significant predictor of depression (Penwell-Waines et 
al., 2017; Skorvanek et al., 2015). Eight of the studies 
found a positive relationship between stigma and 
anxiety, with higher stigma associated with increased 
anxiety (from medium to large effects; Jesus-Ribeiro et 
al., 2017; Penwell-Waines et al., 2017; Valvano et al., 
2016; Simpson et al., 2014; Gallagher et al., 2010; 
Carod-Artal et al., 2008; Luo et al., 2005; Martínez-
Martín et al., 2005). Three studies found non-significant 
relationships between stigma and anxiety/depression 
when measured using the UPDRS-I (Tu et al., 2017; 
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Skorvanek et al., 2015; Martínez-Martín et al., 2005). 
However, Martínez-Martín et al. (2005) also examined 
the constructs of anxiety and depression in more detail, 
using the HADS and found significant relationships of 
medium and large effect size, respectively. Similarly, Tu 
et al. (2017) examined depression using the Geriatric 
Depression Scale and reported a significant relationship 
of medium effect. These findings suggest that the 
UPDRS-I may not be sensitive enough to measure 
anxiety and depression in this population.    
There appears to be no effect for the relationship 
between psychosis (which includes hallucinations) and 
stigma experience (Skorvanek et al., 2015). A small 
effect was reported by Gallagher et al. (2010; r = .26); 
however, the overall methodological quality of this study 
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is poor and has limited generalisability to a PD 
population.  
Where stigma was measured against other 
psychological factors, significant relationships have 
been documented for; apathy (Skorvanek et al., 2015), 
stress (Simpson et al., 2014) and cognitive fusion (the 
tendency to view thoughts as facts and perceive these 
as unchangeable; Valvano et al., 2016). 
A limited number of the included studies examined the 
relationship between positive factors of psychological 
wellbeing and their association with stigma (Simpson et 
al., 2014; Airlie et al., 2001). Airlie et al. (2001) found 
that greater levels of stigma are associated with lower 
self-efficacy (one’s perceived ability to overcome 
challenges). Simpson et al. (2014) found a non-
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significant relationship between stigma experience and 
positive affect.   
In summary, there appears to be strong and consistent 
findings for the relationship between stigma and 
measures of psychological distress, in particular anxiety 
and depression. 
Health-Related Quality of Life 
Ten of the reviewed studies examined overall HRQoL 
and different aspects of HRQoL, including activities of 
daily living, pain, and sleep/fatigue (Tu et al., 2017; 
Jesus-Ribeiro et al., 2017; Valvano et al., 2016; 
Skorvanek et al., 2015; Hechtner et al., 2014; Simpson 
et al., 2014; Gallagher et al., 2010; Carod-Artal et al., 




The relationship between stigma and HRQoL was 
examined in two studies (Valvano et al., 2016; Hechtner 
et al., 2014). Hechtner et al. (2014) examined the 
predictive power of stigma across five European 
countries (UK, France, Germany, Italy and Spain) and 
reported that stigma was a significant predictor of 
HRQoL for France only, when controlling for age, 
gender, disease stage and duration.  Similarly, in a 
North American study, Valvano et al. (2016) reported 
that stigma was a significant predictor of HRQoL when 
controlling for cognitive fusion. 
Activities of daily living 
How stigma influences activities of daily living and social 
roles was examined across four of the reviewed studies 
(Simpson et al., 2014; Carod-Artal et al., 2008; Luo et 
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al., 2005; Martínez-Martín et al., 2005). Consistent 
associations between stigma experience and activities 
of daily living were reported at a small to medium effect. 
Three studies reported a medium effect size between 
stigma and aspects of daily living and stigma and self-
care (e.g. dressing and washing self and attending work; 
Simpson et al., 2014; Carod-Artal et al., 2008; Luo et al., 
2005). These results indicate that higher reports of 
stigma are related to lower activities of daily living. Only 
one study reports a non-significant effect between 
stigma and activities of daily living (Martínez-Martín et 
al., 2005); however, this study included mild PD 





Five of the reviewed studies examined the relationship 
between stigma and pain; the relationship had mixed 
findings (Jesus-Ribeiro et al., 2017; Gallagher et al., 
2010; Skorvanek et al., 2015; Luo et al., 2005; Martínez-
Martín et al., 2005). Two studies reported a significant 
relationship between stigma and the experience of pain 
(Gallagher et al., 2010; Jesus-Ribeiro et al., 2017). Both 
studies suggest that greater levels of pain are 
associated with higher reports of personal experience of 
stigma. However, three studies report a non-significant 
relationship between stigma and pain (Skorvanek et al., 
2015; Luo et al., 2005; Martínez-Martín et al., 2005). 
Sleep and Fatigue 
Four of the reviewed studies examined the relationship 
between stigma and sleep/fatigue (Martínez-Martín et 
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al., 2005; Skorvanek et al., 2015; Tu et al., 2017; 
Gallagher et al., 2010). Three studies report a non-
significant relationship between these factors (Martínez-
Martín et al., 2005; Skorvanek et al., 2015; Tu et al., 
2017). Gallagher et al. (2010) report a significant 
relationship between stigma and sleep/fatigue. When 
compared with Gallagher et al. (2010) the overall quality 
of the studies that report a non-significant relationship 
was higher. Thus, at present, there appears to be no 
relationship between stigma and sleep/fatigue.  
In summary, stigma appears to be correlated with 
activities of daily living, with higher reports of stigma 
associated with reduced activities of daily living. Mixed 
findings are present for the relationship between stigma 
and pain. There appears to be no clear evidence of a 
relationship between stigma and fatigue, and stigma and 
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sleep. There is growing evidence to suggest that stigma 
is a predictor of HRQoL. 
Discussion 
Key Findings 
The findings of this review indicate that there is a 
complex relationship between stigma and demographic, 
illness, psychological and quality of life factors.  
Two studies found a significant relationship between 
stigma and age, with younger individuals reporting 
higher levels of stigma (Carod-Artal et al., 2007; 
Skorvanek et al., 2015). The significant findings by 
Carod-Artal et al., (2007) and Skorvanek et al. (2015) 
may be understood from the perspective that younger 
individuals may experience higher levels of scrutiny by 
peers, and physical appearance may be considered of 
greater value compared to older aged individuals 
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(Tiggemann & Lynch, 2001). Younger individuals may 
have a greater feeling of pressure to appear similar to 
their social group in order to be accepted by others. This 
may reflect similarities with Goffman’s work, as 
individuals wish to align themselves with particular social 
groups (Goffman, 1963). In addition, it may be that older 
aged individuals may have more coping strategies and 
are more resilient to the effects of stigma (Gooding, 
Hurst, Johnson & Tarrier, 2012). It has also been 
reported that with age, there is an expectation of 
physical health decline and this may be perceived as 
less disruptive to an individual’s sense of self (Bury, 
1982; Faircloth, Boylestein, Rittman, Young & Burium, 
2004). However, the effect of condition severity over 
time as the illness progresses may be conflating the 
relationship between age and stigma. In contrast, two 
papers have reported a non-significant relationship 
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between stigma and age (Simpson et al., 2014; Zhao et 
al., 2008). Therefore, it remains unclear if a relationship 
exists given that only two studies found this effect. It 
could be argued that studies with higher methodological 
rigor found no effect, thus from two studies alone, there 
appears to be no strong evidence of a relationship 
between stigma and age. This may also reflect a decline 
in stigma experience for individuals beyond the age of 
65, due to expectations of illness with increasing age.  
From the studies which examined the relationship 
between stigma and condition severity (Skorvanek et al., 
2015; Gallaher et al., 2010), it appears that the 
experience of stigma may be associated with 
physiological decline. These results support Goffman’s 
views on visible difference leading to an increase in 
stigmatisation (Goffman et al., 1963). The findings also 
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support the notion of visibility identified by Jones (1984) 
which suggests that as the course of the condition 
develops, the effects may be more visible to others 
which increases the risk of stigma. Equally, an individual 
experiencing the condition may become more aware of 
the extent of its visibility and perceive themselves to be 
stigmatised. With progressive illness an individual’s 
physical functioning may decrease and this may impact 
upon their perception of; control (MacCarthy & Brown, 
1989), self-worth (Baker & Graham, 2004) and stigma 
(Ma et al., 2016). 
When examining the relationship between stigma and 
psychological factors, the weight of findings appears to 
suggest that stigma is associated with higher depression 
(10 studies) and higher anxiety (7 studies). Increasing 
symptoms of condition severity is associated with feeling 
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less valued (Scambler, 1989) and a reduction in the 
perception of capabilities (De Ridder, Geenen, Kuijer, & 
van Middendorp, 2008) and self-efficacy (Marks & 
Allegrante, 2005). Low self-efficacy is associated with 
depression (Soysa & Wilcomb, 2015). Furthermore, 
experiencing increasing symptoms may serve to disrupt 
the dynamic of social interactions or lead to individuals 
isolating themselves, which again may lead to 
depression (Jones, 1984; Hermanns, 2013). With 
increasing symptoms, the aesthetic quality of the 
condition becomes more visible. This may hinder social 
interactions further. While depression may be a 
consequence of stigma, it may also in turn increase 
stigma perceptions. Individuals who experience 
depression can perceive situations more negatively, 
thus, may report more experiences of stigma (Gotlib, 
1983). The direction of this relationship is currently 
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unknown and further research is required to determine if 
a uni or bi-directional relationship exists between these 
variables. 
A number of studies found a relationship between 
stigma and factors associated with HRQoL, such as 
activities of daily living. The results in this area suggest 
that higher levels of stigma are associated with reduced 
perceptions of daily functioning. Stigma may influence 
an individual’s ability to take part in everyday or social 
functions (Jesus-Ribeiro et al, 2017). This may be due to 
individuals’ concerns or experiences of appearing 
different to others in society (Goffman; 1963). An 
individual who has increased symptoms of PD may be at 
greater risk of experiencing stigma and as a result may 
have restricted social functioning. Jones’ (1984) account 
of concealment may provide some explanation of the 
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relationship between stigma and activities of daily living, 
including social functioning. Individuals may become 
more aware of the condition due to its visibility and again 
this may result in stigma which could lead to an 
individual isolating themselves or reducing their activities 
(Hermanns, 2013). Life satisfaction is often obtained 
through participation and enjoyed activities. For 
individuals who experience chronic and progressive 
conditions, where participation is more challenging or no 
longer possible, this is likely to affect self-perception (De 
Ridder et al., 2008). Thus, with time, individuals may 
participate less (Thordardottir, Nilsson, Iwarsson, & 
Haak, 2014).  
Link and Phelan’s (2001) stigma definition suggests, that 
stigma occurs in societies that allow processes of 
labelling, stereotyping and devaluing to occur. This may 
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explain the importance of geography and culture for the 
stigma experience (Klepac et al., 2007; Hechtner et al., 
2014). Given that the effect of country and culture was 
not examined in other studies in this review, replications 
are required before further conclusions can be drawn. 
There are contrasting results reported in a number of 
studies that examined aspects of HRQoL, such as the 
relationship between stigma and pain, and stigma and 
sleep/fatigue. Direct comparison of the papers’ findings 
is challenging due to the varied scales adopted in each 
study. Therefore, further replication of studies is required 
before conclusions can be drawn. The underlying 
relationship between stigma and aspects of HRQoL for 
individuals with neurodegenerative conditions concerned 
in this review remains unclear.  
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Stigma and the significantly associated factors of 
condition severity, psychological wellbeing and HRQoL, 
may impact each other in a bidirectional relationship. 
Further research is required to determine the direction of 
these associations using more powerful statistical 
techniques. 
Implications and recommendations 
The weight of evidence in this review points to a 
relationship between higher stigma and increased 
psychological distress, particularly in the form of anxiety 
and depression. Therefore, it may be necessary for 
interventions to target both sides of this relationship at a 
community and an individual level (reducing both stigma 
and psychological difficulties). For health professionals 
this may take the form of awareness raising and 
information sharing about the condition and its effects on 
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the individual and wider systems. Developing a greater 
public understanding may help to reduce any concerns 
or misconceptions surrounding the condition which may 
also serve to diminish stigmatisation. 
Experiences of stigma may result in an individual feeling 
worthless, less valued by others and may be associated 
with symptoms of depression (Carod-Artal et al., 2008). 
Therefore, it is important for individuals with these 
conditions to feel included and valued as an individual 
and not defined by their condition.  
To assist with inclusion beyond the context of family and 
health care settings, it is the responsibility of health care 
professionals to increase societal awareness of these 
conditions. This may be achieved through the effective 
use of advertising campaigns across a broad spectrum 
of media formats, from written documents to social 
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media platforms. This would target a wide range of 
individuals and increase societal understanding of 
neurodegenerative conditions (Parkinson’s UK). For 
example, raising public awareness has been shown to 
reduce stigmatisation for individuals who experience 
Alzheimer’s dementia (Devlin, MacAskill, & Stead, 
2007). 
In addition, specific psychological interventions may be 
appropriate for individuals with these neurodegenerative 
conditions to reduce anxiety and depression. For 
example, acceptance and commitment therapy (ACT; 
Hayes, Strosahl, & Wilson, 1999) promotes acceptance 
and the pursuit of action in line with an individual’s 
values. This approach has been shown to increase 
psychological flexibility, decrease self-stigma (Luoma, & 
Platt, 2015) and reduce anxiety and depression 
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(Forman, Herbert, Moitra, Yeomans, & Geller, 2007). 
Cognitive fusion has been found to mediate the 
relationship between stigma and emotional wellbeing 
(including anxiety, depression and HRQoL; Valvano et 
al., 2016). Depression and anxiety were also found to 
mediate the relationship between stigma and cognitive 
fusion (Valvano et al., 2016). ACT directly targets 
cognitive fusion to promote increased flexibility of 
thought, thereby having the potential to reduce the 
detrimental effect of stigma on psychological wellbeing.  
Utilising a narrative approach, self-advocacy and group 
therapy (White & Epston,1990), helps individuals to 
‘thicken’ their identity in a strengths-based manner. This 
may help individuals to take notice of their own value 
and see themselves as more than just their condition. 
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Compassion focused therapy (CFT; Gilbert, 2009) has 
also been efficacious in reducing the effect of health-
related stigma (Luoma & Platt, 2015). It has been shown 
that developing compassion towards the self, may act as 
a coping resource which individuals could utilize in the 
event of a distressing experience (Terry & Leary, 2011). 
Cultivating compassion can reduce anxiety (Gilbert & 
Procter, 2006) and depression (Diedrich, Grant, 
Hofmann, Hiller, & Berking, 2014).  
Review strengths and limitations 
Within this review attempts were made to maximise the 
search strategy and ensure relevant results were 
captured. Considering these neurodegenerative 
conditions together in terms of their visible motor 
difficulties enables inferences to be developed using a 
larger evidence base.  However, as the search did not 
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identify any results relevant to the conditions of 
MND/ALS and HD, future studies that focus on these 
conditions are required.  
Furthermore, all studies were cross-sectional in design, 
therefore longitudinal studies are also required to 
establish if relationships change over the life course. 
The data examined in this review illustrates the 
relationship between two variables; however, neither 
direction nor causality can be inferred. Further research 
is required which examines the relationships using more 
statistically powerful techniques to further our 
understanding of direction of relationships.   
Across the twenty studies, five different measures were 
used to assess stigma. All measures for stigma were 
self-report. The stigma scales varied in length, ranging 
from one item to twenty-two items, and clearly the 
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shorter scales could not capture the complexity of the 
construct. Furthermore, none of the scales differentiated 
between perceived and enacted stigma; thus, our 
understanding is limited of how different aspects of 
stigma may be related to psychological wellbeing. It may 
be useful for further research to concentrate on the 
development of more sensitive scales which are able to 
identify the subtleties of stigma in relation to its 
component parts. For example, the Stigma Scale for 
Chronic Illnesses (SSCI) is well-validated for use with 
individuals who have neurodegenerative conditions 
(Molina, Choi, Cella & Rao, 2013) and is able to 
distinguish between perceived versus enacted stigma 
(Rao, et al., 2009). Moreover, this information will assist 
with appropriate and potentially more cost-effective 
intervention development. For example, if sensitive 
stigma measures indicate that enacted stigma is 
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important for wellbeing, then interventions at a systemic 
and societal level may be most appropriate. Further to 
this, the study by Airlie et al. (2001) used a stigma scale 
which was developed for use with individuals with 
epilepsy (Tedman et al.,1995). The scale was used for a 
sample of individuals with MS, however there was no 
justification for this and the authors gave no indication 
that the scale had been validated with this population. In 
addition, when examining the scale, the language used 
appeared to be culturally specific, utilising idioms and 
expressions which may not be familiar to a 
contemporary, cross-culturally diverse sample 
(Nordmann & Jambazova, 2017). It is therefore useful to 
consider how scales are developed and used within a 
cultural and condition-specific context. Self-report 
measures are culturally sensitive, with individuals from 
Western and non-Western backgrounds showing 
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differences in the degree to which they can hold both 
positive and negative beliefs regarding a particular 
concept (Spencer-Rodgers, Peng, Wang & Hou 2004). 
Given that little information was reported on the 
background of individuals who took part in the studies, 
greater demographic detail would help to examine the 
cultural differences with stigma experience.  
Conclusion 
This review aimed to examine the relationship between 
stigma and demographic, social and clinical factors for 
individuals with specific neurodegenerative conditions.  
The findings indicate that stigma is related to condition 
severity, psychological factors and perceptions of 
HRQoL.  Future research should statistically examine 
the relationships between stigma and demographic, 
social and clinical variables using more complex models 
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to determine if bidirectional relationships exist.  By 
furthering our understanding of the relationships 
between stigma and these variables, clinical practice 
can be enhanced at an individual and community level.  
Policies and campaigns should aim to increase 
awareness and understanding of these 
neurodegenerative conditions in order to acknowledge 
difference and promote inclusion.  
Health professionals and third sector organisations have 
a responsibility to educate and raise awareness on the 
nature and impact of these conditions. Locating change 
at a societal level may help towards preventing 
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Appendix A. Quality appraisal checklist  
Checklist 
This checklist has been developed for assessing the validity of studies reporting 
correlations. It is based on the appraisal step of the 'Graphical appraisal tool for 
epidemiological studies (GATE)', developed by Jackson et al. (2006). 
This checklist enables a reviewer to appraise a study's internal and external validity 
after addressing the following key aspects of study design: characteristics of study 




There are 5 sections of the revised GATE. Section 1 seeks to assess the key 
population criteria for determining the study's EXTERNAL VALIDITY – that is, the extent 
to which the findings of a study are generalisable beyond the confines of the study to 
the study's source population. 
Sections 2 to 4 assess the key criteria for determining the study's INTERNAL 
VALIDITY – that is, making sure that the study has been carried out carefully, and that 
the identified associations are valid and are not due to some other (often unidentified) 
factor. 
Checklist items are worded so that 1 of 5 responses is possible: 
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++ Indicates that for that particular aspect of study 
design, the study has been designed or conducted in 
such a way as to minimise the risk of bias. 
+ Indicates that either the answer to the checklist 
question is not clear from the way the study is 
reported, or that the study may not have addressed 
all potential sources of bias for that particular aspect 
of study design. 
− Should be reserved for those aspects of the study 





Should be reserved for those aspects in which the 
study under review fails to report how they have (or 






Should be reserved for those study design aspects 
that are not applicable given the study design under 
review (for example, allocation concealment would 
not be applicable for case–control studies). 
 
In addition, the reviewer is requested to complete in detail the comments section of the 
quality appraisal form so that the grade awarded for each study aspect is as 
transparent as possible. 
Each study is then awarded an overall study quality grading for internal validity (IV) and 
a separate one for external validity (EV): 
• ++ All or most of the checklist criteria have been fulfilled, where they have not been 
fulfilled the conclusions are very unlikely to alter. 
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• + Some of the checklist criteria have been fulfilled, where they have not been fulfilled, 
or not adequately described, the conclusions are unlikely to alter. 
• – Few or no checklist criteria have been fulfilled and the conclusions are likely or very 
likely to alter. 
Checklist 
STUDY IDENTIFICATION: Include full citation details 
  
STUDY DESIGN: 
Refer to the glossary of study designs (appendix D) and the algorithm 
for classifying experimental and observational study designs (appendix 





SECTION 1: POPULATION 
1.1 IS THE SOURCE POPULATION OR SOURCE 
AREA WELL DESCRIBED? 
• Was the country (e.g. developed or non-
developed, type of health care system), setting 
(primary schools, community centres etc), 
location (urban, rural), population demographics 







1.2 IS THE ELIGIBLE POPULATION OR AREA 
REPRESENTATIVE OF THE SOURCE 








• Was the recruitment of individuals, clusters or 
areas well defined (e.g. advertisement, birth 
register)? 
• Was the eligible population representative of the 
source? Were important groups 
underrepresented? 
NA 
1.3 DO THE SELECTED PARTICIPANTS OR 
AREAS REPRESENT THE ELIGIBLE 
POPULATION OR AREA? 
• Was the method of selection of participants from 
the eligible population well described? 
• What % of selected individuals or clusters agreed 
to participate? Were there any sources of bias? 










SECTION 2: METHOD OF SELECTION OF EXPOSURE (OR 
COMPARISON) GROUP 
2.1 SELECTION OF EXPOSURE (AND 
COMPARISON) GROUP. HOW WAS SELECTION 
BIAS MINIMISED? 







2.2 WAS THE SELECTION OF EXPLANATORY 
VARIABLES BASED ON A SOUND THEORETICAL 
BASIS? 
• How sound was the theoretical basis for selecting 









2.3 WAS THE CONTAMINATION ACCEPTABLY 
LOW? 
• Did any in the comparison group receive the 
exposure? 







2.4 HOW WELL WERE LIKELY CONFOUNDING 
FACTORS IDENTIFIED AND CONTROLLED? 
• Were there likely to be other confounding factors 
not considered or appropriately adjusted for? 







2.5 IS THE SETTING APPLICABLE TO THE UK? 









SECTION 3: OUTCOMES 
3.1 WERE THE OUTCOME MEASURES AND 
PROCEDURES RELIABLE? 
• Were outcome measures subjective or objective 
(e.g. biochemically validated nicotine levels ++ vs 
self-reported smoking −)? 
• How reliable were outcome measures (e.g. inter- 
or intra-rater reliability scores)? 
• Was there any indication that measures had been 
validated (e.g. validated against a gold standard 









3.2 WERE THE OUTCOME MEASUREMENTS 
COMPLETE? 
• Were all or most of the study participants who 
met the defined study outcome definitions likely 







3.3 WERE ALL THE IMPORTANT OUTCOMES 
ASSESSED? 
• Were all the important benefits and harms 
assessed? 
• Was it possible to determine the overall balance 








3.4 WAS THERE A SIMILAR FOLLOW-UP TIME IN 






• If groups are followed for different lengths of time, 
then more events are likely to occur in the group 
followed-up for longer distorting the comparison. 
• Analyses can be adjusted to allow for differences 




3.5 WAS FOLLOW-UP TIME MEANINGFUL? 
• Was follow-up long enough to assess long-term 
benefits and harms? 







SECTION 4: ANALYSES 
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4.1 WAS THE STUDY SUFFICIENTLY POWERED 
TO DETECT AN INTERVENTION EFFECT (IF ONE 
EXISTS)? 
• A power of 0.8 (i.e. it is likely to see an effect of a 
given size if one exists, 80% of the time) is the 
conventionally accepted standard. 
• Is a power calculation presented? If not, what is 








4.2 WERE MULTIPLE EXPLANATORY VARIABLES 
CONSIDERED IN THE ANALYSES? 
• Were there sufficient explanatory variables 









4.3 WERE THE ANALYTICAL METHODS 
APPROPRIATE? 
• Were important differences in follow-up time and 







4.6 WAS THE PRECISION OF ASSOCIATION 
GIVEN OR CALCULABLE? IS ASSOCIATION 
MEANINGFUL? 
• Were confidence intervals or p values for effect 
estimates given or possible to calculate? 
• Were CIs wide or were they sufficiently precise to 
aid decision-making? If precision is lacking, is this 







SECTION 5: SUMMARY 
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5.1 ARE THE STUDY RESULTS INTERNALLY 
VALID (I.E. UNBIASED)? 
• How well did the study minimise sources of bias 
(i.e. adjusting for potential confounders)? 





5.2 ARE THE FINDINGS GENERALISABLE TO 
THE SOURCE POPULATION (I.E. EXTERNALLY 
VALID)? 
• Are there sufficient details given about the study 
to determine if the findings are generalisable to 
the source population? 
• Consider: participants, interventions and 
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The purpose of this study was to investigate whether the 
perception of control mediates the relationship between 
stigma and wellbeing in people with Parkinson’s 
disease.  
Design 
A survey of quantitative, cross-sectional design was 
used. Data were analysed using mediation regression 
analyses.     
Method 
Adults with Parkinson’s disease were invited to take part 
in a survey online, or by paper on request. 
Two hundred and twenty-nine individuals completed 
quantitative measures of stigma and perceived control, 
and a full exploration of the concept of wellbeing 
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(including health-related quality of life, depression, 
anxiety, stress and positive affect).  
Results  
Mediational regression analyses indicated that the 
perception of control mediated the relationship between 
stigma and a number of factors: health-related quality of 
life, depression and positive affect. Perceived control did 
not, however, mediate the relationship between stigma 
and anxiety nor between stigma and stress. 
Conclusion 
These findings suggest that in people with Parkinson’s 
disease, perceived control may play an important role in 
explaining the relationship between stigma and some 
aspects of wellbeing. Perceived control should be 
considered within clinical and everyday environmental 
settings, to target the relationship between stigma and 
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wellbeing, for individuals with Parkinson’s disease. 
Interventions which focus on increasing perceived 
control (e.g. cognitive behaviour therapy), and how 
these may affect stigma and wellbeing are outlined.  
Keywords: Stigma, perceived control, HRQoL, 
wellbeing, neurodegenerative, Parkinson’s disease, 
anxiety, depression, stress, positive affect. 
Parkinson’s disease is a neurodegenerative condition 
affecting 27 in every 10,000 individuals in the UK 
(Parkinson’s UK, 2009), and one percent of those over 
60 years of age internationally (Dorsey et al., 2007; Hirtz 
et al., 2007). Individuals are likely to experience tremor, 
rigidity and slowness of movement, as the primary motor 
problems (Jankovic, 2008). Individuals may also have 
cognitive, sleep and psychological difficulties (Menza & 
Marsh, 2006). These experiences – including both those 
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more directly disease-related and those associated with 
living with such a condition - can result in visible 
difference, and difference within society can be 
associated with stigma (Jones et al., 1984).  
Classic accounts of stigma suggest it occurs in response 
to characteristics that deviate from the social norm and 
are considered to be of less value (e.g., Goffman, 1963). 
Stigma can involve direct acts from others (e.g. being 
called derogatory names, or being stared at), and may 
be felt by an individual with PD as a result of 
internalising negative societal stereotypes (Scambler, 
1989). 
Stigma has been shown to be related to a range of 
negative outcomes including reduced social support, 
occupational loss and social exclusion (Goffman, 1963; 
Weiner, Perry & Magnusson, 1988). Stigma is also 
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associated with increased reports of shame, 
embarrassment and poor self-esteem in general 
research (Link & Phelan, 2001; Rao et al., 2009) and in 
people with PD (Maffoni, Giardini, Pierobon, Ferrazzoli & 
Frazzitta, 2017; Schrag, Jahanshah & Quinn, 2001).  
The relationship between stigma and psychological 
wellbeing is complex. For some individuals with 
Parkinson’s, there appears to be an association 
between stigma experiences and high anxiety and 
depression (Carod-Artal et al., 2008; Jesus-Ribeiro, 
Vieira, Ferreira, Januário & Freire, 2017; Luo et al., 
2005; Simpson, Lekwuwa, & Crawford, 2014). For 
others, the experience of stigma does not appear to 
correlate with some indicators of wellbeing e.g. anxiety 
and depression (Skorvanek et al., 2015) and positive 
affect (Simpson et al., 2014). Therefore, there may be 
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other factors that influence the effect of stigma on 
indices of wellbeing.   
One variable which might explain the differing effects on 
stigma on measures associated with well-being is 
perceived control, understood as the level of control felt 
by an individual generally (i.e. over their life) or, as is 
more usual in health psychology, in health-related 
contexts. Control as a concept has been extensively 
used as both a predictor and outcome measure in health 
psychology (e.g. Eccles & Simpson, 2011), is included in 
a number of theoretical models (e.g. self-regulatory 
model: Leventhal, Leventhal & Cameron, 2001) and has 
been shown to predict well-being, with higher levels of 
control generally (although with some important caveats) 
predicting higher levels of well-being. Interestingly, the 
theoretical construct has also been identified by 
Parkinson’s UK members, in response to a general 
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survey, as important to wellbeing (Parkinson’s UK, 
2015). For individuals with chronic health conditions, 
high levels of perceived control are generally associated 
with high scores of health-related quality of life (HRQoL) 
and low levels of anxiety, depression and negative affect 
(Hagger & Orbell, 2003; Leventhal, Nerenz & Steele, 
1984).  
Obtaining a sense of perceived control over PD is 
challenging due to the chronic, unpredictable and 
degenerative nature of the condition. However, it is 
possible for individuals with PD to gain a sense of 
control over other aspects of their lives (Eccles & 
Simpson, 2011; Eccles, Murray & Simpson, 2011) or 




Given the significance of perceived control for 
individuals with PD, it could be hypothesised that 
perceived control underpins the relationship between 
stigma and wellbeing and so acts as an important 
mediating variable. The aim of this study was to test this 
theoretical assumption via a mediation analysis.  It is 
accepted that wellbeing is a well-used term with no fixed 
and agreed definition (e.g. Ryff & Keyes, 1995). 
Wellbeing in this study was characterised by both the 
absence of mental health difficulties (i.e. as measured 
by depression and anxiety scales) and by the presence 
of positive affect. It also included a measure of health-
related quality of life (HRQoL). HRQoL is a multi-
dimensional concept which provides a more holistic 
account of individuals’ levels of satisfaction over a 
number of life domains (Fallowfield, 1990). Two 
measures of perceived control were incorporated (a 
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general/non-health specific measure, and a Parkinson’s 
disease specific measure). Both these measures were 
used in order to assess whether control operated at a 
generic level or in relation to the specifics of living with 
Parkinson’s.  
Consequently, as has been outlined above, the model 
being tested is that perceived control mediates the 
relationship between stigma and measures of wellbeing. 
While of theoretical interest, this model would also have 
implications relevant to clinical psychology both in 
individual formulations and in in relation to societal 
impact (see also Simpson, McMillan & Reeve, 2013). 
It is hypothesised from the research reviewed that high 
levels of stigma would be associated with high levels of 
anxiety, depression, stress and reduced HRQoL and 
positive affect. It was also hypothesised, again based on 
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previous research, that perceived control (on both 
scales) would positively correlate with HRQoL and 
positive affect and negatively correlate with depression, 
anxiety and stress. It is therefore hypothesised that 
perceived control may play a mediating role in the 
relationship between the assumed predictor (stigma) 
and each aspect of wellbeing measured.    
Method 
Design 
The study was a cross-sectional survey comprised of 
quantitative measures. The data were examined using 
mediation analysis. Mediation analysis was conducted 
using Hayes PROCESS tool (Hayes, 2013) to examine 
whether perceived control mediated the relationship 
between stigma and wellbeing. Figure 1 shows a path 




• Individuals who self-reported a diagnosis of PD 
• Individuals who were 18 years or above 
• The survey as written in English, thus, participants 
required sufficient knowledge of written English to 
take part  
• Participants were able to complete the survey 
measures either alone or with support.  
Participants 
All participants were recruited from a large UK-based 
PD charity (Parkinson’s UK). The study was advertised 
online by the charity from September 2017 to December 
2017. Individuals who met the inclusion criteria were 
eligible to participate in the study (see inclusion criteria). 
Two hundred and fifty individuals participated in the 
survey. Twenty participants were removed due to large 
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amounts of missing data (twelve provided only 
demographic information, two missed one measure and 
six missed more than one measure). A Kolmogorov-
Smirnov (K-S) test was not conducted, due to the large 
sample size in this study, as samples larger than 100 
participants lead to an increase in the chance of Type I 
error (Field, 2013). Thus, normality of the data was 
assessed by visual inspection, using histograms and 
boxplots. These indicated one extreme data point which 
was removed from the dataset. The remaining dataset 
consisted of 229 participants. Methods of mean 
imputation and pro-rating of individual cases was used 
for 14 participants due to small amounts of missing data, 















Figure 1. Path diagram.  
Parameters A, B and C’ denote path (regression) 
coefficients. 
Materials 
The survey included demographic and clinical questions 
alongside validated measures. 
The demographic variables collected were; age, gender, 
ethnicity, work status, relationship status and living 










home). The clinical variables collected were; age of 




The Stigma Scale for Chronic Illness (SSCI; Rao et al., 
2009) measures both perceived and enacted stigma and 
has been validated for use with individuals with 
neurological conditions such as PD (Molina, Choi, Cella 
& Rao, 2013). This 24-item scale was developed to 
gather information about individuals’ feelings towards 
their experience of having a neurological condition. The 
scale consists of 2 subscales; perceived stigma and 
enacted stigma. The perceived stigma subscale 
contains 13 questions about an individual’s feelings 
regarding their condition, focusing on any worries or 
feelings of embarrassment. Answers are given on a 5-
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point Likert scale from 1 = never, to 5 = always, with 
scores ranging from 13 to 65. The enacted subscale 
consists of 11 items with scores range between 11 and 
55. Questions relate to an individuals’ objective 
experience of stigma such as noticing people staring. 
Scores on the two subscales are summed to create a 
total stigma score. Higher scores indicate higher 
experiences of stigma. The scale is reported to have 
good content and internal validity (Stevelink, Wu, 
Voorend & van Brakel, 2012), and good internal 
consistency with a Cronbach’s alpha of 0.92 
(Anagnostouli et al., 2016). 
Mediator Variables 
The Parkinson’s UK Scale of Perceived Control 
(PUKSoPC) was developed with Parkinson’s UK 
members and has been comprehensively validated 
(Simpson, Chatzidamianos, Fletcher, Perpetuo, & 
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Eccles, 2018). The scale consists of 15 items with five 
subscales: Think positive, Get informed, Do things, 
Make plans, and Be involved, rated on a 5-point Likert 
scale. There are three questions within each subscale 
that are summed, with the total score for subscales 
ranging from 3 to 15. Subscales can also be summed to 
form an overall score for the scale, which may range 
from 15 to 75. Higher scores indicate greater perceived 
control. The internal consistency for the overall score of 
the scale has been reported at .92; along with the 
Cronbach’s alpha for each of the subscales (Think 
positive: .87, Get informed: .77, Do things: .86, Make 
plans: .79, Be involved: .80; Simpson et al., 2018). 
The General Self-Efficacy Scale (GSE; Jerusalem & 
Schwarzer, 1992) was used as a general/non-health 
specific measure of perceived control. It assesses 
individuals’ general beliefs in their ability to respond to 
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and problem solve situations. The scale is 
unidimensional, consisting of 10 questions with 
response options on a 4-point Likert scale (1 = not at all 
true, to 4 = exactly true), with possible scores ranging 
from 10 to 40. The scale is a reliable and valid measure 
for use with individuals experiencing PD (Nilsson, Hagell 
& Iwarsson, 2015). Internal consistency of the scale has 
been reported at .76 to .90 across 23 nations 
(Schwarzer & Jerusalem, 1995). 
Outcome Variables 
The Parkinson’s Disease Questionnaire (PDQ) was 
used to measure health-related quality of life (Jenkinson 
et al., 2012). This is a short form consisting of 8 items 
which have been taken from a larger 39-item measure 
(PDQ-39; Jenkinson et al., 1998). The short form 
consists of items measuring mobility, activities of daily 
living, emotional wellbeing, social support, cognitions, 
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communication, bodily discomfort and stigma. 
Respondents are asked to rate items for how frequently 
they experience difficulty in that domain. Items are rated 
on a 5-point Likert scale (1 = Never, to 5 = 
Always/Cannot do at all), with total scores ranging from 
8-40. Lower scores indicate higher HRQoL, while higher 
scores indicate the reverse. This scale has been found 
to be a valid and reliable measure which can be used 
cross-culturally (Jenkinson & Fitzpatrick, 2007), with an 
internal consistency of .74. 
The Depression Anxiety and Stress Scale-21 (DASS-21; 
Lovibond & Lovibond, 1995) is a well-validated short-
form version of the original scale (Henry & Crawford, 
2005) and has been used with the PD population 
(Birtwell, Dubrow-Marshall, Dubrow-Marshall, Duerden, 
& Dunn, 2017). The short-version is considered to be 
more acceptable to individuals completing the measure 
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(Henry & Crawford, 2005). The measure consists of 
three subscales:  depression, anxiety, and stress. 
Subscales include 7 items and individuals indicate on a 
4-point Likert scale whether items have been relevant to 
them in the past few weeks (response options range 
from 0 = does not apply, to 3 = applies very much/most 
of the time). Total scores range from 0-63, with higher 
scores indicating more severe depression, anxiety or 
stress. The internal consistency for the DASS total score 
has been reported at .93, and for each of the subscales: 
depression at .88, anxiety at .82, and stress at .90 
(Henry & Crawford, 2005). 
The positive subscale of the Positive and Negative 
Affect Schedule (PANAS; Watson, Clark & Tellegen, 
1988) was used to measure positive affect in PD in the 
last few weeks. Only the 10-item positive subscale was 
administered as, the DASS already provided an 
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assessment of negative mood. The measure is rated on 
a 5-point Likert scale (1 = very slightly or not at all, 5 = 
extremely), with total scores ranging from 10-50. Higher 
scores represent higher levels of positive affect. The 
PANAS is a reliable and valid measure of positive affect 
in non-clinical populations (Crawford & Henry, 2004) and 
has been used in people with Parkinson’s (Simpson, 
Lekwuwa & Crawford, 2013). Internal consistency 
(Cronbach’s alpha) was reported for the positive 
subscale at .86-.90 (Watson, Clark & Tellegen, 1988).  
All measures were formatted to facilitate online use. 
Procedure 
Parkinson’s UK advertised the study to members of the 
charity on their website. After reading the advertisement, 
participants could select an option to find out further 
information where they were redirected to a page hosted 
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by Qualtrics (2013) regarding the study. Participants 
then read an information sheet about the study and 
consented to take part in the research. When consent 
had been given, the online survey was made available 
(see Section 4 for survey). Participants were given the 
option to complete a paper survey. Two individuals 
requested paper copies, which were sent directly to be 
returned free of charge. The survey took approximately 
30 minutes to complete. Data from paper versions were 
inputted into Qualtrics (by the researcher). Data were 
downloaded from Qualtrics site to create an electronic 
dataset.  
Data analysis 
The study was powered to find a medium effect size for 
both the relationship between stigma and perceived 
control, and the relationship between perceived control 
and wellbeing within the mediation. A minimum number 
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of 71 participants were required to provide a sufficiently 
powered study of .8, with a significance value of p <.05 
(Fritz & MacKinnon, 2007).  
The data were assessed for normality to ensure that no 
extreme data points would influence the model. The 
data were then analysed using inferential statistics. 
Pearson’s r correlations were conducted to determine 
the relationship of the predictor, demographic or clinical 
variables to the outcome variables.  
Mediational regression analyses were conducted to 
determine if the perception of control mediated the 
relationships between stigma and wellbeing.   
Inferential analysis 
Pearson’s correlation coefficients were conducted 
between each outcome variable and 
demographic/psychosocial variables. The data were 
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then statistically examined using a mediational 
regression and only significant correlations (p < .05) 
were entered into the model (Field, 2013). Hayes 
PROCESS tool (Hayes, 2013), which implements a 
bias-corrected bootstrap model, was utilised to conduct 
the mediation regression. A bootstrap sample (of 1000 
replications) was used in the analyses. Utilising 
bootstrapping techniques allows powerful statistical 
analyses to be conducted without having to meet the 
requirements of normality assumptions (Efron, 1987).  
Results 





Table 1. Descriptive Statistics of the sample  
 Value Range 
Age: mean (SD)   
Age in years 65 (8.00) 29-90 
Age of symptom onset 57 (9.74) 26-90 
Age of diagnosis 60 (9.32) 29-90 
Gender: n (%)   
Female 116 (51) - 
Male 113 (49) - 
Ethnic group: n (%)   
White  227 (91) - 
Asian 2 (9) - 
Partnership status: n (%)   
Single 18 (8) - 
Married 191 (83) - 
Divorced 10 (4) - 
Widowed 10 (4) - 
Living arrangements: n (%)   
Alone 37 (16) - 
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With others (partners, 
family and friends) 
190 (83) - 
Residential/nursing home 1 (0.5) - 
Other 1 (0.5) - 
Work Status:   
Employed 42 - 
Other (including retired) 187 - 
Note: Percentages are rounded to the nearest whole 
number, except for percentages less than one, which 
are rounded to the nearest 0.5%. SD: standard 
deviation. 
From the 229 participants who took part in the study, the 
mean age of the sample was 65 years (with a range of 
44-93 years). Of the sample, 113 participants reported 
their gender as male, and 116 as female. Two hundred 
and twenty-seven individuals identified themselves as 
white, with 2 reporting being from an Asian background. 
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Of the 42 participants who identified as employed, 41 
individuals provided information on their hours worked. 
This ranged from 10-70 hours per week. From the hours 
of work provided, 14 participants (34%) worked for 40 
hours or more per week, 18 (44%) worked between 30-
39 hours per week, 5 (12%) worked between 20-29 
hours per week, and 4 (10%) worked between 10-19 
hours per week.   
Clinical characteristics of the sample 
Of the individuals who reported age of symptom onset (n 
= 228), this ranged from 26-90 years. The majority of 
scores (71%) were between the ages of 50-69 years.  
Of the participants who reported the age at which PD 
was diagnosed (n = 228), this ranged from 29-90 years. 
The majority of participants (72%) were diagnosed with 
PD between the ages of 50-69 years. 94% of 
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participants reported taking prescribed medication to 
manage the symptoms of PD. 
Validated measures 
See Table 2 for means, standard deviations (SD) and 
Cronbach’s alpha of psychometric measures for the 
sample.  
Table 2. Means, SDs and Cronbach’s alpha of 
psychometric variables 































Sample averages were interpreted using normative data 
and clinical cut off scores (Lovibond & Lovibond, 1995; 
Jenkinson & Fitzpatrick, 2007; Watson, Clark and 
Tellegen, 1988; Schwarzer, & Jerusalem, 1995; 
Simpson, Chatzidamianos, Fletcher, Perpetuo & Eccles, 
2018; Molina, Choi, Cella & Rao, 2013). The mean of 
the sample indicated generally low levels for depression 
(in the mild range) which suggests that the sample were 
not experiencing difficulties with negative affect 
(Lovibond & Lovibond, 1995). The sample mean for 
anxiety fell within the higher range, indicating that the 
sample may have been experiencing moderately high 
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levels of anxiety (Lovibond & Lovibond, 1995). The 
sample mean for stress fell within the normal range, 
suggesting that on average the sample did not 
experience severe difficulties with stress (Lovibond & 
Lovibond, 1995). The mean of the sample for HRQoL 
was moderately low, indicating higher than average 
HRQoL (Jenkinson & Fitzpatrick, 2007). The mean 
score for PANAS was moderately high, indicating high 
levels of positive affect for the sample (Watson, Clark 
and Tellegen, 1988).  
The sample reported generally high scores for GSE and 
PUKSoPC, which indicates high levels of perceived 
control (Schwarzer & Jerusalem, 1995; Simpson et al. 
2018). The mean sample score for stigma was low, 
which suggests that the sample experienced low levels 
of stigma (Molina, Choi, Cella & Rao, 2013). 
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Overall, the scores indicate diverse experiences of 
stigma, perceived control and wellbeing. The sample 
means indicate that participants may have struggled 
with anxiety more than low mood or stress.  
Inferential analyses  
Correlational analyses  
Prior to mediation regression, bivariate Pearson’s 
correlations were carried out on the demographic and 
psychosocial variables (see Table 3a and 3b for details). 
All variables relating to the study’s hypotheses (stigma, 






Table 3a. Correlates of demographic and validated measures  
  SSCI 
PUK- 
SoPC GSE PDQ DASS-D DASS-A DASS-S PANAS 
Age -.14* .08 .02 .02 -.06 -.13 -.14* .05 
Gender .11 .04 -.15* -.02 -.02 .01 -.02 -.21 
Work status -.08 .20** -.04 .05 -.04 -.08 -.01 .08 
Relationship 
status 
.11 -.14* -.10 .12 .17* .14* .16* -.13 
Living 
status 




-.28** .09 .12 -.14* -.12 -.14* -.14* .09 
Age of 
diagnosis 
-.29** .09 .13 -.14* -.12 -.13 -.12 .09 
Prescribed 
medication 
-.10 .01 .10 -.11 -.05 -.04 -. 01 .06 
Note: *p value is less than .05. **p value is less than .01. 
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Table 3b. Correlations between validated measures 
  SSCI 
PUK- 
SoPC GSE PDQ DASS-D DASS-A DASS-S PANAS 
SSCI - -.40** -.40** .69** .60** .46** .53** -.45** 
PUKSoPC -0.40** - .52** -0.40** -0.46** -0.20 -0.28** .66** 
GSE -0.39** 0.52** - -0.49** -0.48** -0.28** -0.30** 0.69** 





The SSCI correlated with all psychometric outcome 
measures (DASS; PDQ; PANAS) and both measures of 
perceived control (PUKSoPC; GSE). Significant 
correlations were found between the SSCI and DASS-D, 
DASS-A and DASS-S, indicating that higher 
experiences of stigma were associated with greater 
levels of depression, anxiety and stress. Significant 
negative correlations were found between the SSCI and 
PDQ, and the SSCI and PANAS, indicating that higher 
stigma scores were associated with lower quality of life 
and positive affect. Significant negative correlations 
were found between the SSCI and both measures of 
perceived control (PUKSoPC; GSE). This suggests that 
higher stigma scores were associated with lower scores 
of perceived control. 
Significant relationships were found between both 
measures of perceived control (PUKSoPC; GSE) and all 
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psychometric outcomes variables. Significant negative 
correlations were found between both measures of 
perceived control (PUKSoPC; GSE) and DASS-D, 
DASS-A, and DASS-S, indicating that higher levels of 
perceived control were associated with lower levels of 
depression, anxiety and stress. Significant correlations 
were found between both measures of perceived control 
(PUKSoPC; GSE) and PDQ and PANAS, indicating that 
higher levels of perceived control are associated with 
increased HRQoL and positive affect.  
A number of demographic variables correlated with 
outcome variables.  Significant correlations were found 
between relationship status and depression and stress, 
and living arrangements and depression and stress; 
indicating that individuals not with a partner, or living 
alone, reported higher levels of depression and stress. 
Significant correlations were also found between age of 
176 
 
symptom onset and PDQ, and age of diagnosis and 
PDQ, indicating that individuals who experience 
symptoms at an older age, or who were diagnosed at an 
older age reported higher HRQoL. These demographic 






Mediational regression analyses were performed and 
then re-examined while controlling for covariates. Tables 





Table 4. Mediation Models with PUK as mediator  
 Model 1 
X = stigma 
M = control 
Y = HRQoL 
Model 2 
X = stigma  
M = control 
Y = anxiety 
Model 3 
X = stigma  
M = control 
Y = depression 
Model 4 
X = stigma 
M = control 
Y = stress 
Model 5 
X = stigma 
M = control 
Y = positive 
affect 
A      
b -0.26** -0.26** -0.26** -0.26** -0.26** 
CI -0.34, -0.18 -0.34, -0.18 -0.34, -0.18 -0.34, -0.18 -0.34, -0.18 
B      
b -0.09* -0.01 -0.26** -0.08 0.52** 
CI -0.16, -0.03 -0.11, 0.09 -0.37, -0.15 -0.19, 0.03 0.43, 0.62 
C’      
b 0.26** 0.23** 0.32** 0.30** -0.13** 
CI 0.22, 0.31 0.16, 0.29 0.25, 0.39 0.22, 0.37 0.19, 0.07 
AB      
b 0.02 0.003 0.07 0.02 -0.14 
CI 0.01, 0.05 -0.03, 0.03 0.03, 0.11 -0.01, 0.06 -0.19, -0.09 
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CSIE 0.06 - 0.11 - -0.23 
Note: A = (M*X); B = (M*Y); C’ = direct effect of X on Y, controlling for M; C = total 
effect of X on Y, not controlling for M; AB = proportion of effect that is mediated; b = 
mediated/indirect effect (A*B); CI = confidence interval; CSIE: completely standardised 





Table 5. Mediation Models with PUK as mediator, with covariates 
 Model 1 
X = stigma 
M = control 
Y = HRQoL 
Covariates: Age 
of symptom 
onset; age of 
diagnosis 
Model 2 
X = stigma  
M = control 







X = stigma  
M = control 






X = stigma 
M = control 





A     
b -0.26** -0.26** -0.26** -0.26** 
CI -0.35, -0.18 -0.34, -0.18 -0.34, -0.18 -0.33, -0.18 
B     
b -0.09* -0.01 -0.25** -0.07 
CI -0.16, -0.03 -0.10, 0.09 -0.36, -0.14 -0.18, 0.04 
C’     
b 0.27** 0.22** 0.31** 0.29** 
CI 0.23, 0.32 0.15, 0.29 0.24, 0.39 0.22, 0.37 
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AB     
b 0.25 0.01 0.06 0.02 
CI 0.01, 0.05 -0.03, 0.03 0.03, 0.11 -0.02, 0.06 
CSIE 0.06 - 0.10 - 
Note: A = (M*X); B = (M*Y); C’ = direct effect of X on Y, controlling for M; C = total 
effect of X on Y, not controlling for M; ab = proportion of effect that is mediated; b = 
mediated/indirect effect (a*b); CI = confidence interval; CSIE: completely standardised 









Table 6. Mediation Models with GSE as mediator  
 Model 1 
X = stigma 
M = control 
Y = HRQoL 
Model 2 
X = stigma  
M = control 
Y = anxiety 
Model 3 
X = stigma  
M = control 
Y = depression 
Model 4 
X = stigma 
M = control 
Y = stress 
Model 5 
X = stigma 
M = control 
Y = positive 
affect 
A      
B -0.16** -0.16** -0.16** -0.16** -0.16** 
CI -0.21, -0.11 -0.21, -0.11 -0.21, -0.11 -0.21, -0.11 -0.21, -0.11 
B      
B -0.27** -0.14 -0.46** -0.17 0.89** 
CI -0.37, -0.17 -0.29, 0.02 -0.63, -0.29 -0.35, 0.01 0.74, 1.03 
C’      
B 0.25** 0.21** 0.31** 0.29** -0.12** 
CI 0.21, 0.29 0.15, 0.27 0.24, 0.38 0.22, 0.36 -0.18, -0.07 
AB      
B 0.04 0.01 0.07 0.02 -0.14 
CI 0.02, 0.07 -0.01, 0.03 0.03, 0.12 -0.01, 0.07 -0.20, -0.09 
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CSIE 0.10 - 0.07 - -0.24 
Note: A = (M*X); B = (M*Y); C’ = direct effect of X on Y, controlling for M; C = total 
effect of X on Y, not controlling for M; AB = proportion of effect that is mediated; b = 
mediated/indirect effect (a*b); CI = confidence interval; CSIE: completely standardised 




Table 7. Mediation Models with GSE as mediator, with covariates 
 Model 1 
X = stigma 
M = control 




onset; age of 
diagnosis 
Model 2 
X = stigma  
M = control 







X = stigma  
M = control 






X = stigma 
M = control 





A     
b -0.15** -0.15** -0.15** -0.15** 
CI -0.20, -0.10 -0.20, -0.10 -0.20, -0.11 -0.20, -0.11 
B     
b -0.28** -0.13 -0.45** -0.16 
CI -0.38, -0.17 -0.28, 0.03 -0.62, -0.28 -0.34, 0.02 
C’     
b 0.26** 0.20** 0.31** 0.29** 
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CI 0.21, 0.30 0.14, 0.27 0.24, 0.38 0.21, 0.36 
AB     
b 0.04 0.01 0.03 0.01 
CI 0.02, 0.07 -0.003, 0.03 0.02, 0.07 -0.002, 0.03 
CSIE 0.10 - 0.07 - 
Note: A = (M*X); B = (M*Y); C’ = direct effect of X on Y, controlling for M; C = total 
effect of X on Y, not controlling for M; AB = proportion of effect that is mediated; b = 
mediated/indirect effect (a*b); CI = confidence interval; CSIE: completely standardised 




Model 1: Mediational regressions for stigma, 
perceived control and HRQoL  
Mediation analyses indicated that stigma significantly 
predicted perceived control (pathway A: b = -0.26, 95% 
CI [-0.34, -0.18], p < .001) and perceived control 
predicted ratings of HRQoL (PDQ) (pathway B: b = -
0.09, 95% CI [-.16, -0.03], p < .05; see table 4). 
Perceived control was found to be a significant mediator 
within the model (pathway AB: b = 0.02), with the 
confidence interval not crossing zero (BC 95% CI [0.01, 
0.05]); this indicates that perceived control plays a 
mediating role in the relationship between stigma and 
HRQoL. 
The direct effect between stigma and HRQoL was found 
to be significant when controlling for the effect of the 
mediational variable of perceived control (Cꞌ: b = 0.26, 
95% CI [0.22, 0.31], p < .001). The completely 
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standardised indirect effect indicates that as stigma 
increased by 1 SD, PDQ scores increased by 0.06 SD 
due to the effect of perceived control. Thus, as a result 
of the influence of perceived control, as stigma 
increased, HRQoL decreased. 
When controlling for the variables of age, symptom 
onset and age of diagnosis, all pathways of the model 
remained significant (see Table 5 for details) and the 
completely standardized indirect remained the same 
(0.06).  
Model 2: Mediational regressions for stigma, 
perceived control and anxiety 
The second unadjusted mediation model found stigma 
to significantly predict perceived control (pathway A: b = 
-0.26, 95% CI [-0.34, -0.18], p < .001; see table 4). 
Perceived control did not significantly predict anxiety in 
188 
 
the model (pathway B: b = -0.01, 95% CI [-0.11, 0.09], p 
> .05). The overall indirect effect was (pathway AB: b = 
0.003) and the confidence interval contained zero (BC 
95% CI [-0.03, 0.03]) suggesting that there was a non-
significant effect for the mediating role of perceived 
control within the model. 
When adjusting for the variables of age, symptom onset 
and relationship status, again only pathway A was 
significant within the model (see Table 5 for details).  
Model 3: Mediational regressions for stigma, 
perceived control and depression  
The third unadjusted mediation model found stigma to 
significantly predict perceived control (pathway A: b = -
0.26, 95% CI [-0.34, -0.18], p< .001; see table 4). 
Perceived control significantly predicted depression in 
the model (pathway B: b = -0.26, 95% CI [-0.37, -0.15], 
189 
 
p < .001). The overall indirect effect for perceived control 
(pathway AB: b = 0.07), was found to be significant with 
a confidence interval that did not contain zero (BC 95% 
CI [0.03, 0.11]). This indicates that perceived control 
plays a mediating role in the relationship between 
stigma and depression. The direct effect between stigma 
and depression remained significant when controlling for 
the effect of the mediational variable of perceived control 
(Cꞌ: b = 0.32, 95% CI [0.25, 0.39], p < .001). The 
completely standardised indirect effect indicates that as 
stigma increased by 1 SD, DASS-D scores increased by 
0.11 SD, thus, as stigma increased, depression 
increased as a result of perceived control. 
When adjusting for the variables for relationship status 
and living arrangements, all pathways of the model 
remained significant (see Table 5 for details) and the 
completely standardised indirect effect reduced (0.10).  
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Model 4: Mediational regressions for stigma, 
perceived control and stress 
The fourth unadjusted mediation model found stigma to 
significantly predict perceived control (pathway A: b = -
0.26, 95% CI [-0.34, -0.18], p < .001; see table 4). 
Perceived control was not a significant predictor of 
stress in the model (pathway B: b = -0.08, 95% CI [-
0.19, 0.03], p > 0.05). The overall indirect effect for 
perceived control (pathway AB: b = 0.02), was found to 
be non-significant with a confidence interval that 
contained zero (BC 95% CI [-0.01, 0.06]). This suggests 
that perceived control did not play a mediating role in the 
relationship between stigma and stress.  
When adjusting for the variables of living arrangements 
and relationship status within the model, again only 
pathway A was significant (see Table 5 for details) 
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Model 5: Mediational regression for stigma, 
perceived control and positive affect 
The fifth unadjusted mediation model found stigma to 
significantly predict perceived control (pathway A: b = -
0.26, 95% CI [-0.34, -0.18], p < .001; see table 4). 
Perceived control was a significant predictor of positive 
affect (pathway B: b = 0.52, 95% CI [0.43, 0.62], p < 
.01). The overall indirect effect for perceived control 
(pathway AB: b = -0.14), was found to be significant with 
a confidence interval that did not cross zero (BC 95% CI 
[-0.19, -0.09]). This suggests that perceived control 
mediated the relationship between stigma and the 
experience of positive affect. 
The direct effect between stigma and positive affect was 
found to be significant when controlling for the effect of 
the mediational variable of perceived control (Cꞌ: b = -
0.13, 95% CI [0.19, 0.07], p < .001). The completely 
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standardised indirect effect indicates that as stigma 
increased by 1 SD, PANAS scores decreased by -0.23 
SD, thus, as stigma increased, positive affect decreased 
due to the effect of perceived control. 
There were no covariates that correlated with positive 
affect. Thus, an adjusted mediational regression was not 
required. 
Mediational regressions using the GSE 
The GSE was interchanged as the mediator in the 
regression analyses, to examine if the results were 
comparable to those with the PUKSoPC as mediator.  
Table 6 indicates that the results of the GSE were 
similar to those for the PUKSoPC. All pathways showed 
the same direction of the relationship between the 
predictor, mediator and outcome. All the PUKSoPC 
significant pathways were also found to be significant 
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when the GSE was used as mediator. When controlling 
for confounds in the model, the significant pathways 
remained similar to the unadjusted GSE model and 
comparable to the adjusted PUKSoPC (see Table 7). 
The two models which were found to be non-significant 
using the PUKSoPC as mediator (DASS-A; DASS-S) 
were also found to be non-significant when the GSE was 
used. When the mediator was changed, the completely 
standardised indirect effect was comparable to that of 
the PUKSoPC (see Table 6). 
Discussion 
This study examined whether the perception of control 
plays a mediating role in the relationship between 




Stigma correlated with all outcome measures in the 
expected direction (greater stigma, poorer wellbeing). 
Moderate effect sizes were found between stigma and 
perceived control, positive affect and anxiety. Large 
effect sizes were found between stigma and stress, 
depression and HRQoL  
Perceived control significantly mediated the relationship 
between stigma and HRQoL, depression and positive 
affect. All pathways within these models were 
significant, including when covariates were controlled 
for. The largest completely standardised effect size was 
for the mediated relationship between stigma and 
positive affect.  
Perceived control did not mediate the relationship 
between stigma and anxiety and stress.  
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The mediating effect of perceived control supports the 
importance placed upon it within health behaviour 
models such as Leventhal’s self-regulatory model of 
illness representation (Leventhal, Nerenz & Steele, 
1984). This model provides a framework of 
understanding how an individual’s health beliefs may 
facilitate adjustment to a health condition (Leventhal, 
Nerenz & Steele, 1984). Control is an important 
component of these beliefs and the model cumulatively 
can explain the various influences on and responses to 
a chronic condition such as PD. In addition, the current 
findings provide further support to the growing literature 
that emphasises the role of perceived control (Felton & 
Revenson, 1984), particularly for those with PD 
(Simpson, Lekwuwa & Crawford, 2013). From a 
theoretical perspective, the association between the loss 
of control and depression has long been established in 
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empirical research (Seligman & Groves, 1970). For 
example, learned helplessness may arise as a result of 
having limited or no control and this  state has been 
associated with negative affect and is often considered 
to lead to depression (Nowicka-Sauer et al., 2017).  
However, the lack of a relationship between stigma, 
control and anxiety, while not hypothesised, is also 
consistent with other research.  In this current study, 
both measures of perceived control (PUKSoPC; GSE) 
were only weakly associated with anxiety, and neither 
were a predictor of anxiety in regression models. Other 
research reports a weak or no association between 
perceived control and anxiety (Evans & Norman, 2009; 
Simpson et al., 2013), and a non-significant predictive 
effect of perceived control on anxiety in PD (Evans & 
Norman, 2009) and MS (Jopson & Moss-Morris, 2003; 
Vaughan, Morrison & Miller, 2003). Thus, although the 
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finding that perceived control did not mediate nor predict 
anxiety in the models was initially surprising, research 
supports the non-significant relationship within more 
complex statistical analyses.  The implications from 
these findings suggest that targeting interventions that 
focus on increasing perceived control, may not be as 
effective in decreasing anxiety or stress for individuals 
with PD who report stigma. Interventions, therefore, 
should focus on decreasing stigma in society which 
would have a beneficial effect on reducing anxiety and 
stress for individuals with PD.  
Clinical Implications 
Interventions should acknowledge the effect of stigma, 
through the direct pathway and the indirect pathway, via 
perceived control. Reducing stigma is complicated and 
requires coordinated effort on a number of levels 
(Corrigan, 2004). Successful anti-stigma campaigns are 
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notoriously difficult to achieve for health-related 
conditions (Evans-Lacko, London, Little, Henderson & 
Thornicroft, 2010) and the challenges in achieving this 
should not be underestimated. However, approaches 
should aim to decrease stigma experiences by a number 
of different routes including by increasing societal 
awareness of PD (Devlin, MacAskill & Stead, 2007). 
Clinical psychologists may assist with this aim, by 
sharing information to aid public understanding. 
Information provision is a major component of all stigma 
reduction campaigns (Byrne, 2000) but also needs to be 
supplemented by rigorous efforts to address misleading 
information or discriminatory practices. Developing a 
greater public understanding may help reduce any 
concerns or misconceptions surrounding the condition, 
which may also serve to diminish stigmatisation. This 
could be achieved by utilising Parkinson UK’s expertise 
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in designing campaigns, in order to target stigma 
associated with the condition. Utilising this expertise is 
beneficial given that stigma is socially constructed, and 
also perceived control is impacted by broader societal 
issues. Developing stigma-reducing campaigns may 
also encourage individuals to become more involved 
with organisations such as Parkinson’s UK and may 
lead to a two-fold benefit of reducing stigma and 
increasing individuals’ perceived control.  
In addition, clinical psychologists could inform guidelines 
for professionals working with individuals with PD (see 
British Psychological Society, 2009) in order to reduce 
stigma and enhance perceptions of control, HRQoL and 
emotional wellbeing.  
It is likely that interventions that aim to increase 
perceived control may also be beneficial in increasing an 
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individual’s wellbeing and may counter the effect of 
stigma. Cognitive behavioural therapy (CBT) has been 
shown to be effective in increasing individuals’ 
perception of control and emotional wellbeing (Kroenke, 
& Swindle, 2000). While individual therapy has shown to 
be effective in increasing perceived control, it is not the 
only approach to influencing an effect on perceived 
control. It is likely that obtaining a sense of perceived 
control can be gained from a number of factors, and it 
may be useful to consider using broad systemic 
approaches. Individuals with PD are acting and 
responding to their environment, thus it may be 
beneficial to focus at a systemic level. Family and 
friends of individuals with PD could be informed of the 
importance of perceived control and how it has a 
mediating effect. Family and friends could be made 
aware of what might help to increase perceived control 
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in everyday life for individuals with PD. By sharing this 
level of understanding with family and friends, it may 
help others to think of creative ways to help develop a 
sense of perceived control in everyday life. This 
approach may broaden the applicability of research 
findings to beyond the therapy room. The use of a 
broader community-based approach has been shown to 
increase wellbeing for older adults (Devlin et al., 2007). 
Clinical psychologists could help to generate 
community-based intervention ideas, collaboratively with 
individuals with PD to help increase perceived control.  
Strengths, limitations and proposals for future 
research 
The purpose of this study was to examine the nature of 
the relationship between stigma, perceived control and 
wellbeing. In this way the current research complements 
Parkinson UK’s (2015) strategy of increasing our 
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understanding of control and knowledge of how 
individuals with PD can increase their sense of control. 
Future research could examine whether one of the 
components of stigma predicts certain dimensions of 
HRQoL (e.g. enacted stigma could predict activities of 
daily living). With a greater understanding of stigma (i.e. 
its separate forms and how these are related to the 
individual components of HRQoL) interventions may be 
tailored more appropriately, at either an individual or 
societal level. For example, if enacted stigma plays a 
significant role in HRQoL, it may be more appropriate to 
increase awareness and understanding of the nature of 
PD through various media channels. Having a detailed 
understanding of the type of stigma and its relationships 
may provide a cost-effective use of psychology 
resource.   
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Equally it may be that psychological interventions 
designed to increase emotional wellbeing are likely to 
increase an individual’s sense of control. These 
relationships may be bidirectional and/or circular, 
therefore interventions that enhance wellbeing for 
individuals with PD may reduce stigma experience. For 
example, individuals who have high levels of positive 
affect may perceive their experiences as positive and 
may have less negative bias, compared to individuals 
with higher levels of negative affect. There may be an 
association between individuals with higher levels of 
positive affect, perceiving less experiences of felt 
stigma.  
The use of the member-informed scale of perceived 
control (PUKSoPC) ensures that aspects of control that 
are important for those experiencing PD are examined. 
Thus, the scale is considered to have good face validity 
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(Simpson et al., in press). Utilising two measures of 
control (PUKSoPC and GSE), allowed for comparison of 
the PUKSoPC with the well-validated GSE. When 
examining the data for PUKSoPC and GSE, the patterns 
were similar, with the variance PUKSoPC accounted for 
comparable to that of the GSE. When compared with the 
PUKSoPC, the GSE accounted for more variance in 
HRQoL and less variance for anxiety. However, this 
difference was minimal. As the results from the 
PUKSoPC were comparable to those from the well-
validated GSE, this study presents further validation of 
the PUKSoPC for use with individuals with PD.  
The participants in this study reported low levels of 
stigma, depression and moderately high levels of 
perceived control. Since the majority of the data was 
collected within a short time period (two weeks) and with 
low attrition, it may be suggested that the participants 
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who took part were highly motivated. Notwithstanding 
these factors, the mediating effect of perceived control 
was found in this study. The results of the current paper 
therefore highlight the importance of perceived control in 
explaining some of the relationship between stigma and 
emotional wellbeing and HRQoL. Since perceived 
control has shown a mediating effect in low reported 
stigma conditions it may be useful to capture the 
experience of individuals with PD who report lower 
levels of control, higher levels of stigma and may have 
reduced functioning to examine the mediating strength 
of control. 
The study used online recruitment and was advertised 
through Parkinson’s UK. This may have selected a 
sample of individuals who may be highly literate and/or 
motivated due to the fact that they have proactively 
become a member of a third-sector organisation. 
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Therefore, the findings could be different for individuals 
with PD who do not have computer access or are not 
members of a charity.  
The study was only available in English, and although 
individuals were permitted to complete the survey with 
support, comprehending the survey and the concept of 
stigma may not be translatable to other languages or 
cultures. Individuals from Eastern cultures may be more 
experienced in viewing concepts, such as wellbeing, 
from a dual perspective (Spencer-Rodgers, Peng, Wang 
& Hou, 2004); in turn this may influence their reports of 
the concept and the meaning of the score. Thus, the 
findings of the present study may be limited in its 
generalisability cross-culturally.  
The sample of participants was predominantly white with 
only two individuals identifying themselves as Asian. 
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Thus, this may reduce the representativeness of the 
findings of the study, as the sample may not capture the 
diversity in population of individuals experiencing PD in 
the UK. It may be beneficial for replication to be 
conducted with a sample that more broadly represents 
the population of individuals with PD. This would 
increase the ecological validity and may strengthen the 
findings of the current study and the implications that are 
proposed.  
Given the cross-sectional design of the study, the 
findings provide a snapshot of how perceived control 
affects the relationship between stigma and variables of 
HRQoL. With a progressive condition, such as PD, the 
condition may become more visible and therefore more 
visible to others. Increasing visibility may result in higher 
experiences of stigma (Jones et al., 1984). The 
experience of perceived control may also change over 
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time with a changing course of the condition (Leventhal, 
Nerenz & Steele, 1984). Longitudinal studies may 
provide a more detailed picture of how these 
relationships may change over time. 
Conclusion 
The findings of this study inform our understanding of 
the nature of the relationship between stigma and 
HRQoL and emotional wellbeing for individuals with PD. 
The findings provide further support for the role of 
perceived control in individuals with chronic health 
conditions. Perceived control plays an important role in 
mediating the relationship between stigma and HRQoL, 
stigma and depression and stigma and positive affect. 
Interventions should target control to help enhance 
individuals’ HRQoL and aspects of emotional wellbeing. 
Systemic interventions should be utilised to increase 
control in everyday life for individuals with PD.  
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Interventions should also target stigma and its impact on 
individuals’ wellbeing, through raising awareness and 
public understanding of PD. Future research should 
further examine stigma and its defined forms with the 
individual components of HRQoL, to elucidate the 
relationships further. In addition, conducting more 
complex statistical models would allow for examination 
of more complex relationships including whether 
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The findings that perceived control mediated the 
relationship between stigma and aspects of 
psychological wellbeing and health-related quality of life, 
are critically appraised in this paper. Factors which may 
influence the study findings, such as study design, 
epistemological position and recruitment considerations 
are outlined. Personal reflections of the research 
process and proposals for future research are provided.  
A quantitative study of cross sectional design was used 
to examine whether the perception of control mediates 
the relationship between stigma and factors of 
wellbeing. Correlational analyses indicated that a 
number of demographic and clinical factors significantly 
correlated with the experience of stigma and the 
assessed factors of wellbeing.  
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The study found perceived control to be a significant 
mediator in the relationship between stigma and 
depression, health-related quality of life (HRQoL) and 
positive affect, but not between stigma and anxiety or 
stress.  
The findings indicate the potential importance of 
perceived control in contributing to some aspects of 
wellbeing for individuals with Parkinson’s disease (PD).  
This paper will discuss study design considerations and 
strengths and limitations of the research. Personal 
reflections will be provided and the link between stigma 
and disablism discussed. Considerations for future 





Use of quantitative methods  
I adopted a quantitative methodology to further examine 
the roles of stigma and perceived control. This approach 
allows for information to be gathered on the role that a 
particular variable (e.g. perceived control) may have in 
relation to stigma and wellbeing. The choice of research 
design is underpinned by my epistemological positivist 
perspective that the truth is ‘real’ and discoverable. 
Compared to qualitative approaches, quantitative 
methods facilitate the investigation of concepts and 
experiences that are shared across a particular 
population, thus providing detail that is applicable to 
larger samples. Gaining knowledge of concepts and 
relationships across a larger scale allows for a more 
representative way to apply this information to 
theoretical frameworks. Moreover, the increased 
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representativeness of findings allows for the generation 
of clinical and systemic proposals, which may influence 
future policies and broader service provision. 
Although it may be argued that qualitative approaches 
provide detailed and individualised accounts of 
experiences, the relationships between perceived 
control, stigma and wellbeing have been researched 
from a qualitative perspective (Maffoni, Giardini, 
Pierobon, Ferrazzoli & Frazzitta, 2017).  
Online participation 
The study was advertised online by Parkinson’s UK 
(PUK). Since the researchers at Lancaster University 
have established good links with the charity, this may 
have helped in obtaining feedback on the proposed 
study and the recruitment of individuals. PUK have a 
large and active group of individuals who are willing to 
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take part in research. The participant quota for the 
survey was reached in under one week. This may 
indicate that using online research for individuals with 
PD is an acceptable medium. The study was designed 
to enable individuals to save their responses and return 
at a more convenient time should they feel fatigued or if 
they required the survey to be temporarily postponed. 
Although recruiting individuals quickly was beneficial to 
this thesis project, given the short recruitment period 
available, future studies may benefit by having a broader 
advertisement process.  
Being computer-literate is a pre-requisite of participating 
in this study, which may have been a barrier to 
individuals who do not have experience in using 
computers. However human support could have been 
used (e.g. family or friends) and paper versions were 
242 
 
available to facilitate survey completion for individuals. 
Paper versions of the survey were made available upon 
request and were returned freepost. Only two individuals 
stated this preference and returned their questionnaires 
by post. 
The study was advertised online through PUK, thus 
potentially only being accessible to individuals who are 
computer literate who may have higher levels of 
perceived control and higher functioning with PD 
compared to individuals who are not connected to the 
charity.  
PD affects individuals at a later stage in life, therefore 
individuals with PD who are computer-literate may 
reflect a particular demographic which may not be 
representative of the wider PD population. Research 
from the Office for National Statistics in the UK indicates 
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that 4.2 million people aged over the age of 65 have 
never used the internet and only 0.5 million have used it, 
but not in the last 3 months (Age UK, 2016). Therefore, 
using varied recruitment methods may capture a wider 
demographic of individuals with PD experience.   
Completing online surveys has the advantage of wide 
geographical coverage, timely delivery and return, and 
are more cost-effective than hard-copy alternatives 
(Dillman, 2007). However, given the low number of older 
individuals who use the internet it may have been 
beneficial to advertise the study in a paper format. 
Future studies may benefit from providing support with 
survey completion to capture a broad spectrum of 
experience from individuals with PD i.e. those with lower 




When proposing this study, it was considered unlikely to 
lead to distress through participation. Nevertheless, 
details of appropriate support agencies were provided at 
the end of the study. The online, anonymous nature of 
this study does not allow us to assess if the survey 
results in any signs of distress, however, of the 329 
individuals who accessed the survey, none of the 
participants used the given email address to provide 
their comments or feedback on taking part. In addition, it 
may be assumed that the location of the survey on the 
PUK website, may be visible to individuals who are 
active members of the charity and are potentially familiar 
with participating in research.  
The use of validated measures 
The study used a range of validated measures of 
stigma, control and factors of wellbeing. All the 
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measures used Likert scales to assess the factors. 
Using validated and reliable scales ensures that the 
constructs of interest are being measured.  
The Parkinson’s Disease Questionnaire-8 (PDQ-8) 
measures quality of life (Jenkinson, Fitzpatrick, Peto, 
Dummett, Morley et al., 2012). However, one question 
pertains specifically to stigma and therefore there is the 
risk that the relationship between the Stigma Scale for 
Chronic Illnesses (SSCI; Rao, Choi, Victorson, Bode, 
Peterman, et al., 2009) and PDQ-8 is inflated. 
Therefore, the data for the PDQ-8 were re-analysed, 
removing the stigma question. It is acknowledged this 
involves using a measure which properties are no longer 
stable and validated (Spector, 1992). When comparing 
the analyses of the PDQ-7 and PDQ-8 the significant 
effect of the mediator remains, and the completely 
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standardised indirect effect size is extremely similar (see 
Table 1 in appendix for details). Thus, it seems unlikely 
that the findings can be explained by this possible 
conceptual confound.  
Personal reflections 
My own experience of having a health condition has 
drawn me to research within the field of health 
psychology. I have first-hand experience of a condition 
which could be stigmatising and personally identify with 
the importance of control in relation to quality of life. 
Through the exploration of this topic it is hoped that 
individuals with PD will be provided with a societal 
perspective of difference. My professional motivation in 
carrying out this study is to extend my knowledge and 
interest within health psychology. In addition, this study 
contributes to the research base and furthers 
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understanding in the field. Ultimately, I hope that in the 
future this knowledge will be applied to appropriate 
clinical work in health psychology.  
Stigma and Disablism 
As a result of society’s lack of appreciation of difference, 
individuals with PD may experience a range of effects 
which impact their lives. Individuals with PD may feel 
and experience exclusion from society and perceive a 
sense of marginalisation (Maffoni et al., 2017). Society is 
generally constructed to meet the needs of individuals 
without disabilities. Structural barriers exist in society 
which may exclude and isolate individuals who are 
unable to access these arenas in the same way 
(structural disablism; Reeve, 2014 p92). It has been 
reported that individuals without disability can feel 
uncomfortable interacting or relating to individuals with 
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disabilities. These experiences reflect what Reeve 
(2005) has reported as psycho-emotional disablism. 
This is reinforced by the underrepresentation of disabled 
individuals in the media portrayed with meaningful, rich 
lives. Often, when disabled individuals are presented in 
the media the focus is on their disability (indirect 
disablism; Reeve, 2014, p93).  Such cultural norms 
influence both individuals’ perceptions of their own 
disabilities and create societal assumptions and 
stereotypes regarding individuals with disabilities 
(Thomas, 1999). For individuals with disabilities such as 
PD, experiences of direct, indirect and structural 
disablism may result in them developing the belief that 
they are inadequate and less valued; Reeve (2014, p95) 
referred to this as internalised oppression. Such 
individuals may avoid situations, attempt to pass as 
‘normal’, or may over achieve in an attempt to distance 
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themselves from any perceived negative attributions 
related to their visible difference (Campbell, 2009). The 
effect of such stigma may have a detrimental effect on 
an individual’s wellbeing (Reijnders, Ehrt, Weber, 
Aarsland, & Leentjens, 2008).  Thus, interventions need 
to target stigma at a societal level to effect change for 
the individual with difference and increase societal 
understanding and acceptance. 
Future research 
The interrelated nature of stigma, control and well-being 
could be further explored, obtaining depth and richness 
in responses using qualitative methodology. It may also 
be beneficial to explore the related nature of these 
variables with individuals with other neuro-degenerative 
conditions such as Huntington’s disease, motor neuron 
disease and multiple sclerosis. Given the visible 
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differences associated with these conditions it may be 
expected that control may have a similar mediating 
affect between stigma and factors of psychological 
wellbeing.  
When comparing the results of the PUKSoPC and the 
GSE, the findings suggest that the PUK member-
constructed scale of control compared favourably to that 
of the well-validated GSE scale. The co-variance 
between these scales and the outcomes was 
comparable with GSE accounting for a greater amount 
of variance in depression, and PUKSoPC accounting for 
more variance in positive affect. However, the difference 
in the amount of variance was minimal.  
It may be that further studies, in addition to using 
quantitative methods, may complement their findings by 
simultaneously utilising mixed methodology to provide 
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subjective accounts of stigma experience, both 
perceived and enacted, and explore how this might be 
related to the experience of wellbeing for individuals with 
PD.  
Conclusion 
The findings from the empirical paper suggest that it 
may be beneficial for interventions to target stigma and 
perceived control in order to maximise the effect on 
psychological wellbeing. Although there may still be a 
place for individual interventions to tackle individuals’ 
beliefs about visible difference, in my opinion, a broader 
approach is required to target the dimensions that 
underpin experiences of psycho-emotional disablism. In 
order to enhance inclusion, health professionals and 
others need to engage with these concepts and not be 
afraid of using vocabulary such as the word ‘stigma’. 
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Avoiding contentious terms does not equate to the 
absence of experience.   
Ultimately the findings of this study indicate that the 
perceptions of control play a mediating role in the 
relationship between stigma and certain aspects of 
wellbeing for individuals with PD. This suggests that 
increasing control and reducing stigma experience could 
improve psychological wellbeing. 
To promote wellbeing for individuals with PD, health 
professionals should facilitate discussions that focus on 
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Appendix A. Table 1. Mediation model 1 with 
PUKSoPC/GSE as mediator and PDQ-7 as outcome 
variable 
 X = stigma 
M = control 
(PUKSoPC) 
Y = HRQoL  
X = stigma 
M = control 
(GSE) 
Y = HRQoL 
A   
b -0.26** -0.16** 
CI -0.34, -0.18 -0.21, -0.11 
B   
b -0.08* -0.27** 
CI -0.15, -0.18 -0.37, -0.17 
C’   
b 0.22** 0.20** 
CI 0.18, 0.26 0.16, 0.24 
C   
b 0.24** 0.24** 
CI 0.20, 0.28 0.20, 0.28 
AB   
b 0.02 0.04 
CI 0.01, 0.05 0.02, 0.07 
CSIE 0.06 0.11 
Note: A = (M*X); B = (M*Y); C’ = direct effect of X on Y, 
controlling for M; C = total effect of X on Y, not 
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controlling for M; AB = proportion of effect that is 
mediated; b = mediated/indirect effect (a*b); CI = 
confidence interval; CSIE: completely standardised 
indirect effect. * p value is less than .05. ** p value is 
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1.1 Ethics Application 
 




Application for Ethical Approval for Research  
 
for additional advice on completing this form, 
hover cursor over ‘guidance’.   
Guidance on completing this form is also 
available as a word document 
 
 
Title of Project: Stigma, perceived control and 
wellbeing in individuals with Parkinson’s disease 
 
 
Name of applicant/researcher:  Danielle Verity 
ACP ID number (if applicable)*:        
Funding source (if applicable)       




*If your project has not been costed on ACP, you 





Type of study 
 Involves existing documents/data only, or the 
evaluation of an existing project with no direct contact 
with human participants.  Complete sections one, two 
and four of this form 
 Includes direct involvement by human subjects.  





1. Appointment/position held by applicant and 
Division within FHM    Trainee Clinical Psychologist 
 
2. Contact information for applicant: 
E-mail:  d.verity@lancaster.ac.uk    
Telephone:  07872 334 826  (please give a number on 




Address:    Department of Clinical Psychology, Division 
of Health Research, Lancaster University, Lancaster, 
LA1 4YG 
 
3. Names and appointments of all members of the 
research team (including degree where 
applicable) 
 
Danielle Verity, Principal Researcher, Trainee Clinical 
Psychologist 
Fiona Eccles, Lecturer in Health Research 
Jane Simpson, Director of Education, DHR 
 
 
3. If this is a student project, please indicate what 
type of project by marking the relevant box/deleting as 
appropriate: (please note that UG and taught masters 
projects should complete FHMREC form UG-tPG, 
following the procedures set out on the FHMREC 
website 
 
PG Diploma         Masters by research                
PhD Thesis              PhD Pall. Care         
 
PhD Pub. Health            PhD Org. Health & Well 




DClinPsy SRP     [if SRP Service Evaluation, please 
also indicate here:  ]          DClinPsy Thesis   
 
4. Project supervisor(s), if different from applicant: 
Dr Fiona Eccles, Dr Jane Simpson 
 
5. Appointment held by supervisor(s) and 
institution(s) where based (if applicable): Dr Friona 
Eccles (Research Supervisor, Lecturer in Research 
Methods), Dr Jane Simpson (Field Supervisor, Director 
of Education for the Division of Health Research and 
Assistant Dean – Communications and Marketing for the 




Complete this section if your project involves 
existing documents/data only, or the evaluation of 
an existing project with no direct contact with 
human participants 
 
1. Anticipated project dates (month and year)   




2. Please state the aims and objectives of the project 





For additional guidance on data management, please go 
to Research Data Management webpage, or email the 
RDM support email: rdm@lancaster.ac.uk 
3. Please describe briefly the data or records to be 
studied, or the evaluation to be undertaken.  
  
4a. How will any data or records be obtained?    
 
4b. Will you be gathering data from websites, discussion 
forums and on-line ‘chat-rooms’        
4c. If yes, where relevant has permission / agreement 
been secured from the website moderator?        
4d. If you are only using those sites that are open 
access and do not require registration, have you made 
your intentions clear to other site users?       
4e. If no, please give your reasons         
 
5. What plans are in place for the storage, back-up, 
security and documentation of data (electronic, digital, 
paper, etc)?  Note who will be responsible for deleting 
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the data at the end of the storage period.  Please ensure 
that your plans comply with the Data Protection Act 
1998.  
 
6a. Is the secondary data you will be using in the public 
domain?  
6b. If NO, please indicate the original purpose for which 
the data was collected, and comment on whether 
consent was gathered for additional later use of the 
data.   
      
Please answer the following question only if you have 
not completed a Data Management Plan for an external 
funder 
7a. How will you share and preserve the data 
underpinning your publications for at least 10 years e.g. 
PURE?  
 
7b. Are there any restrictions on sharing your data?  
The data will not be made public due to the sensitive 
nature of the information. 
 
8.  Confidentiality and Anonymity 
a. Will you take the necessary steps to assure the 
anonymity of subjects, including in subsequent 
publications?       
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b. How will the confidentiality and anonymity of 
participants who provided the original data be 
maintained?   
 
9.  What are the plans for dissemination of findings from 
the research?  
 
10. What other ethical considerations (if any), not 
previously noted on this application, do you think there 
are in the proposed study?  How will these issues be 
addressed?   
   
  
SECTION THREE 
Complete this section if your project includes direct 
involvement by human subjects 
 
1. Summary of research protocol in lay terms (indicative 
maximum length 150 words):   
The current research aims to examine the relationship 
between perceived stigma, control and psychological 
wellbeing, with individuals with Parkinson’s disease 
(PD). PD affects the motor system, resulting in jerky 
movements, tremor and facial expression which conveys 
less emotion. Such visible symptoms can lead to 
individuals experiencing negative attitudes (stigma) by 
others or perceiving a sense of stigma, within a 
267 
 
particular context. Research have shown that feeling 
stigmatized can result in feeling disempowered and 
negatively impacts upon psychological wellbeing. It is 
thought that the perception of control plays a predictive 
role in the relationship between perceived stigma and 
outcomes of psychological wellbeing. This study aims to 
assess the variables of interest through Qualtrics survey 
and examine their related nature using a mediation 
regression analysis. It is hypothesised that the 
relationship between perceived stigma and indices of 
wellbeing will be mediated by perceived control. 
 
2. Anticipated project dates (month and year only)   
 
Start date:  09/2017  End date: 05/2018 
 
Data Collection and Management 
For additional guidance on data management, please go 
to Research Data Management webpage, or email the 
RDM support email: rdm@lancaster.ac.uk 
 
3. Please describe the sample of participants to be 
studied (including maximum & minimum number, age, 
gender):   
Individuals who self-identify as having Parkinson's 
disease will be eligible to take part in the research.  The 
study will be powered to find a medium effect size for 
both the relationship between stigma and control and 
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the relationship between control and wellbeing. At a 
power of .8 and p<.05 approximately 70 participants will 
be needed (Fritz & MacKinnon, 2007) using a bias-
corrected bootstrap for the mediation model (Hayes, 
2012). The minimum number of participants to ensure the 
study is viable is 70, and the maximum is 150.  
Participants must be aged 18 or over. There will be no 
other age, gender or other demographic restrictions for 
participation in the project.  
Exclusion criteria: The survey will be written in English, 
thus individuals who may not be able to read this 
language will not be eligible for inclusion.  
 
4. How will participants be recruited and from where?  
Be as specific as possible.  Ensure that you provide the 
full versions of all recruitment materials you intend to 
use with this application (eg adverts, flyers, posters). 
The survey will be advertised through Parkinson's UK's 
website, and will invite their members who self- identify 
as having a diagnosis of Parkinson’s Disease to 
participate in the project. In addition, the survey will also 
be advertised on the Lancaster University DClinPsy 
webpage, to enable participants who are not members 
of Parkinson's UK but identify themselves as having PD, 
to participate. By reading about the survey online, the 
participants will be able to access a participant 
information sheet about the survey (which can be 
downloaded should they wish). They will be directed to 
the consent form, and will then be able to access the 
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survey to take part. Participants will also be given the 
option to complete the survey in a paper format, should 
they wish. The contact details of how to obtain a paper 
version will be provided on the participant information 
sheet, and a paper version will be posted to them. 
 
5. Briefly describe your data collection and analysis 
methods, and the rationale for their use.   
Participants will complete a survey either online or on 
paper. 
Individuals will be asked to provide demographic and 
clinical data and complete several validated measures to 
determine if relationships exist between variables.  
 





- Work status 
- Relationship status 






- Age of onset 
- Time since diagnosis 
- Taking medication 
 
Validated Measures: 
- The Depression Anxiety and Stress Scale (DASS-21; 
Lovibond & Lovibond, 1995). This is a well-validated 
short-form version of the original scale (Henry & 
Crawford, 2005) and has been used with a PD 
population (Dubrow-Marshall & Birtwell, 2016). The 
short-version is considered to be more acceptable to 
individuals completing the measure (Henry & Crawford, 
2005). 
- The positive subscale of the Positive and Negative 
Affect Schedule (PANAS; Watson, Clark & Tellegen, 
1988) will be used to measure positive affect in PD in 
the last few weeks. The positive subscale alone will be 
used, as the in-depth evaluation of negative mood will 
be provided by the DASS-21. PANAS is a reliable and 
valid measure of assessing positive and negative affect 
in non-clinical populations (Crawford & Henry, 2004).  
- The Parkinson’s Disease Questionnaire (PDQ-8) will 
be used to measure wellbeing (Jenkinson, Fitzpatrick, 
Peto, Dummett, Morley et al., 2012). 
- The Parkinson’s UK Scale of Perceived Control 
(PUKSoPC-15; Simpson, Chatzidamianos & Eccles, 
2015) will be administered. Parkinson’s UK members 
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helped in the development of this scale and it has been 
initially validated (Simpson et al., 2015).  
- Stigma Scale for Chronic Illness (SSCI-24; Molina, 
Choi, Cella & Rao, 2013) measures both perceived and 
enacted (carried out) stigma.  
- The General Self-Efficacy Scale (GSE-10; Jerusalem & 
Schwarzer, 1992) will be used to assess individuals’ 
general beliefs in their ability to respond and problem 
solve situations. The scale is a reliable and valid 
measure for use with individual’s experiencing PD. 
(Nilsson, Hagell & Iwarsson, 2015). 
 
All data will be collated and downloaded into the 
statistical software package, SPSS. A mediation 
regression analysis will be conducted on the quantitative 
data, to establish if perceived control explains/accounts 
for the relationship between stigma and well-being  
 
6. What plan is in place for the storage, back-up, 
security and documentation of data (electronic, digital, 
paper, etc.)?  Note who will be responsible for deleting 
the data at the end of the storage period.  Please ensure 
that your plans comply with the Data Protection Act 
1998.  
During the data collection, data will be stored within the 
Qualtrics survey, accessible only to the research team 
for this project. For individuals who have completed a 
hard-copy version, the paper consent form will be 
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scanned in and the data inputted onto SPSS. The 
original paper documents will be destroyed immediately 
after data input. At the end of the study the data will be 
sent to the academic supervisor using an electronically 
secure method of data transfer and stored in a 
password-protected file space on the university server or 
Box. Scanned in consent forms and data will be stored 
separately for ten years. It will be the responsibility of 
academic supervisor to delete the data after this time. 
The raw data will not be made publicly accessible on 
PURE due to the sensitive information gathered. 
 
7. Will audio or video recording take place?         no               
  audio              video 
a. Please confirm that portable devices (laptop, USB 
drive etc) will be encrypted where they are used for 
identifiable data.  If it is not possible to encrypt your 
portable devices, please comment on the steps you will 
take to protect the data.  N/A 
 
b What arrangements have been made for audio/video 
data storage? At what point in the research will 
tapes/digital recordings/files be destroyed?  N/A 
 
Please answer the following questions only if you have 




8a. How will you share and preserve the data 
underpinning your publications for at least 10 years e.g. 
PURE?  
The data will be stored for 10 years by the DClinPsy 
research co-ordinator under the direction of the 
Programme Director/Research Director, but will not be 
available on PURE.  
8b. Are there any restrictions on sharing your data ?  
The data provided will be sensitive in nature and will not 
be made publicly available in raw form.   
 
9. Consent  
a. Will you take all necessary steps to obtain the 
voluntary and informed consent of the prospective 
participant(s) or, in the case of individual(s) not capable 
of giving informed consent, the permission of a legally 
authorised representative in accordance with applicable 
law?  yes 
 
b. Detail the procedure you will use for obtaining 
consent?   
Participants will read information about the study prior to 
providing their consent. For participants completing the 
survey online they will tick a series of statements and 
then a final statement saying that they consent to take 
part and the survey will not allow them to proceed until 
these boxes are ticked. For participants who decide to 
complete a paper version, a participant information 
sheet and consent form will be provided. Only 
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participants who have provided their consent and signed 
the form will be entered into the electronic database.   
 
10. What discomfort (including psychological eg 
distressing or sensitive topics), inconvenience or danger 
could be caused by participation in the project?  Please 
indicate plans to address these potential risks.  State the 
timescales within which participants may withdraw from 
the study, noting your reasons. 
 
There are no substantial risks anticipated with 
participating in this study.  It may be possible for 
participants to become distressed while completing the 
survey. Participants will be informed prior to 
commencing the study that they can opt out at any time 
during survey completion. However, due to the 
anonymity of participation, their data cannot be removed 
after they have agreed to take part. After starting the 
survey, participants will have 7 days to complete the 
survey, after this time participants will not be able to edit 
or input data, and responses will be automatically 
submitted. The participant information sheet will include 
sources of support and participants will be reminded of 
these at the end of the electronic survey. 
 
11.  What potential risks may exist for the researcher(s)?  
Please indicate plans to address such risks (for 
example, noting the support available to you; 
counselling considerations arising from the sensitive or 
distressing nature of the research/topic; details of the 
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lone worker plan you will follow, and the steps you will 
take).   
 
No risks anticipated for researcher      
 
12.  Whilst we do not generally expect direct benefits to 
participants as a result of this research, please state 
here any that result from completion of the study.   
 
There will be no direct benefits for participants for taking 
part in the research. However, the findings of the study 
will be shared with Parkinson’s UK and their members. 
Participants will also be able to ask the researcher for a 
copy of the results. 
 
13. Details of any incentives/payments (including out-of-
pocket expenses) made to participants:   
No incentives will be paid. 
 
14. Confidentiality and Anonymity 
a. Will you take the necessary steps to assure the 
anonymity of subjects, including in subsequent 
publications? yes 
b. Please include details of how the confidentiality and 
anonymity of participants will be ensured, and the limits 
to confidentiality.  
Participation will be completely anonymous and no 
directly identifiable information will be gathered. Before 
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completing the survey, participants will be informed that 
they are free to stop the survey at any point, however 
their data cannot be identified for removal.  
 
15.  If relevant, describe the involvement of your target 
participant group in the design and conduct of your 
research.  
 
Parkinson’s UK have previously identified that obtaining 
a sense of control is important for their members. The 
scale of perceived control that will be used has been 
developed by and for its members. Service user 
involvement was sought at the design stage of the 
project and their feedback provided details on the 
acceptability of the study. In addition, they also provided 
information on the content and format, to facilitate 
accessibility and aid engagement. Feedback from the 
Patient and Public Involvement forum group for 
Parkinson’s UK members amended the language of the 
Participant Information Sheet and Consent Form to aid 
clarity. In addition, they highlighted that the benefits for 
members to take part in the study needed to be more 
clearly expressed. Thus, these recommendations were 
addressed prior to submitting to the ethics board.  
 
16.  What are the plans for dissemination of findings 
from the research?  If you are a student, include here 
your thesis.  
The project will be written as a final year thesis project 
for a DClinPsy. In addition, the Parkinson’s UK charity 
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will be informed of the outcome of the study and 
provided with a short report, which states the results and 
implications of the study in language which is accessible 
to charity members and personnel. The findings of the 
study will be submitted to relevant journals and may be 
presented at conferences and will be presented to peers 
and staff at the DClinPsy thesis presentation day. 
17. What particular ethical considerations, not previously 
noted on this application, do you think there are in the 
proposed study?  Are there any matters about which you 
wish to seek guidance from the FHMREC? 
I have a disability and my support worker - Amanda 
Boland, will assist with tasks related to the project. In 
this way, Amanda may have access to the raw data. 
Amanda has been informed of the duty of confidentiality 
and provided her agreement to adhere to ethical 
principles for the purpose of research. 
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SECTION FOUR: signature 
 
Applicant electronic signature: D Verity    
  Date 20.06.17 
Student applicants: please tick to confirm that you have 
discussed this application with your supervisor, and that 
they are happy for the application to proceed to ethical 
review   
Project Supervisor name (if applicable): Dr Fiona 




1. SUBMIT YOUR FHMREC APPLICATION BY 
EMAIL TO DIANE HOPKINS 
(d.hopkins@lancaster.ac.uk) as two separate 
documents: 
i. FHMREC application form. 
Before submitting, ensure all guidance 
comments are hidden by going into ‘Review’ in 
the menu above then choosing show 
markup>balloons>show all revisions in line.   
II. Supporting materials.  
Collate the FOLLOWING MATERIALS FOR 
YOUR STUDY, IF RELEVANT, INTO A 
SINGLE WORD DOCUMENT: 
A. YOUR FULL RESEARCH PROPOSAL 





b. Advertising materials (posters, e-mails) 
c. Letters/emails of invitation to participate 
d. Participant information sheets  
e. Consent forms  
f. Questionnaires, surveys, demographic 
sheets 
g. Interview schedules, interview question 
guides, focus group scripts 
h. Debriefing sheets, resource lists 
 
Please note that you DO NOT need to submit 
pre-existing measures or handbooks which 
support your work, but which cannot be 
amended following ethical review.  These 
should simply be referred to in your application 
form. 
2. Submission deadlines: 
i. Projects including direct involvement of human 
subjects [section 3 of the form was 
completed].  The electronic version of your 
application should be submitted to DIANE 
HOPKINS by the committee deadline date.  
Committee meeting dates and application 
submission dates are listed on the FHMREC 
website.  Prior to the FHMREC meeting you 
may be contacted by the lead reviewer for 
further clarification of your application. Please 
ensure you are available to attend the 
committee meeting (either in person or via 
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telephone) on the day that your application is 
considered, if required to do so. 
ii. The following projects will normally be dealt 
with via chair’s action, and may be submitted at 
any time. [Section 3 of the form has not been 
completed, and is not required]. Those 
involving: 
a. existing documents/data only; 
b. the evaluation of an existing project with 
no direct contact with human participants;  
c. service evaluations. 
3. You must submit this application from your 
Lancaster University email address, and copy 
your supervisor in to the email in which you 







Brooks, N. (1996). Writing a grant application. In Parry, 
G., & Watts, F. (1996). Behavioural and mental 
health research: A handbook of skills and methods. 
London: Psychology Press. 
Crawford, J. R., & Henry, J. D. (2004). The Positive and 
Negative Affect Schedule (PANAS): Construct 
validity, measurement properties and normative 
data in a large non‐clinical sample. British Journal 
of Clinical Psychology, 43(3), 245-265. 
Dubrow-Marshall, L., & Birtwell, K. (2016). Impact of 
mindfulness-based stress reduction on depression, 
anxiety and stress in people with Parkinson’s 
disease. European Health Psychologist, 18, 636.  
Eccles, F. J., & Simpson, J. (2011). A review of the 
demographic, clinical and psychosocial correlates of 
282 
 
perceived control in three chronic motor 
illnesses. Disability and Rehabilitation, 33(13-14), 
1065-1088. 
Fife, B. & Wright, E. (2000). The dimensionality of 
stigma: A comparison of its impact on the self of 
persons with HIV/AIDS and cancer. Journal of 
Health and Social Behaviour, 41(1), 50. 
Fritz, M. S., & MacKinnon, D. P. (2007). Required 
sample size to detect the mediated 
effect. Psychological Science, 18(3), 233-239. 
Garlovsky, J. K., Overton, P. G., & Simpson, J. (2016). 
Psychological predictors of anxiety and depression 
in Parkinson's disease: a systematic review. Journal 
of Clinical Psychology, 72(10), 979-998. 
283 
 
Goffman, E. (1963). Stigma: Notes on the management 
of spoiled identity. New York: Prentice-Hall. 
Hagger, M. S., & Orbell, S. (2003). A meta-analytic 
review of the common-sense model of illness 
representations. Psychology and Health, 18(2), 
141-184. 
Hayes, A. F. (2012). PROCESS: A versatile 
computational tool for observed variable mediation, 
moderation, and conditional process modelling. 
Retrieved from http://www.afhayes.com/ 
public/process2012.pdf 
Harris, P. B., & Sterin, G. J. (1999). Insider's 
perspective: Defining and preserving the self of 




Henry, J. D., & Crawford, J. R. (2005). The short‐form 
version of the Depression Anxiety Stress Scales 
(DASS‐21): Construct validity and normative data in 
a large non‐clinical sample. British Journal of 
Clinical Psychology, 44(2), 227-239. 
Jacoby, A. (1994). Felt versus enacted stigma: A 
concept revisited. Social Science & Medicine, 38(2), 
269-274.  
Jankovic, J. (2008). Parkinson’s disease: clinical 
features and diagnosis. Journal of Neurology, 
Neurosurgery and Psychiatry, 79(4), 368-376. 
Jenkinson, C., Fitzpatrick, R., Peto, V., Dummett, S., 
Morley, D., & Saunders, P. (2012). The Parkinson's 
disease questionnaires: User manual. Oxford: 
Health Services Research Unit. 
285 
 
Jerusalem, M., & Schwarzer, R. (1992). Self-efficacy as 
a resource factor in stress appraisal processes. In 
Schwarzer, R. (2014). Self-efficacy: Thought control 
of action. New York: Taylor & Francis. 
Leroi, I., Collins, D., & Marsh, L. (2006). Non-
dopaminergic treatment of cognitive impairment and 
dementia in Parkinson's disease: A review. Journal 
of The Neurological Sciences, 248(1-2), 104-114.  
Link, B. G., & Phelan, J. C. (2001). Conceptualizing 
stigma. Annual review of Sociology, 27(1), 363-385. 
Lovibond, S. & Lovibond, P. F. (1995). Manual for the 
Depression Anxiety Stress Scales. Sydney: 
Psychology Foundation of Australia.  
Ma, H., Saint-Hilaire, M., Thomas, C., & Tickle-Degnen, 
L. (2016). Stigma as a key determinant of health-
286 
 
related quality of life in Parkinson’s disease. Quality 
of Life Research, 25(12), 3037-3045.  
Maffoni, M., Giardini, A., Pierobon, A., Ferrazzoli, D., & 
Frazzitta, G. (2017). Stigma experienced by 
Parkinson’s disease patients: A descriptive review 
of qualitative studies. Parkinson’s Disease, 2017. 
Major, B., & O'Brien, L. (2005). The social psychology of 
stigma. Annual Review of Psychology, 56(1), 393-
421.  
Menza, M., & Marsh, L. (2006). Psychiatric issues in 
Parkinson's disease. London: Taylor & Francis. 
Molina, Y., Choi, S. W., Cella, D., & Rao, D. (2013). The 
stigma scale for chronic illnesses 8-item version 
(SSCI-8): development, validation and use across 
neurological conditions. International Journal of 
Behavioral Medicine, 20(3), 450-460. 
287 
 
Nilsson, M. H., Hagell, P., & Iwarsson, S. (2015). 
Psychometric properties of the General Self‐
Efficacy Scale in Parkinson's disease. Acta 
Neurologica Scandinavica, 132(2), 89-96. 
Obeso, J., Olanow, C., & Nutt, J. (2000). Levodopa 
motor complications in Parkinson's disease. Trends 
in Neurosciences, 23.  
Parkinson's UK. (2009). Parkinson's Prevalence in the 
United Kingdom. Retrieved from 
https://www.parkinsons.org.uk/sites/default/files/par
kinsonsprevalenceuk_0.pdf 
Rao, D., Choi, S., Victorson, D., Bode, R., Peterman, A., 
Heinemann, A., & Cella, D. (2009). Measuring 
stigma across neurological conditions: The 
development of the stigma scale for chronic illness 
(SSCI). Quality oLife Research, 18(5), 585-595.  
288 
 
Robson, C. (2002). Real world research. Oxford: 
Blackwell. 
Simpson, J., Lekwuwa, G., & Crawford, T. (2013). 
Illness beliefs and psychological outcome in people 
with Parkinson’s disease. Chronic Illness, 9(2), 165-
176. 
Simpson, J., Chatzidamianos, G., & Eccles, F.  
(2015). The Parkinson’s UK Scale of Perceived  
Control: Scale construction and initial  
validation. Lancaster University.  
Schrag, A., Jahanshahi, M., & Quinn, N. P. (2001). 
Psychological Medicine. 31(1), 65-73. 
Schwarzer, R., & Jerusalem, M. (1995). Generalized 
Self-Efficacy Scale. In Johnston, M., Wright, S., & 
Weinman, J. (1995). Measures in Health 
289 
 
Psychology: A User's Portfolio. Windsor: NFER-
Nelson. 
Watson, D., Clark, L., & Tellegen, A. (1988). 
Development and validation of brief measures of 
positive and negative affect: The PANAS scales. 
Journal of Personality and Social Psychology, 
54(6), 1063-1070.  
Zampieri, M., & Pedroso de Souza, E. A. (2011). Locus 
of control, depression, and quality of life in 
Parkinson’s disease. Journal of Health 








Stigma, perceived control and wellbeing in 




Name: Danielle Verity 





Parkinson’s disease (PD) is a neurodegenerative 
condition, which primarily affects the motor system, 
resulting in tremor, rigidity and slowness of movement 
(Jankovic, 2008). However, other difficulties are also 
often present including problems with sleep and 
cognition as well as psychological difficulties such as 
low mood and anxiety (Menza & Marsh, 2006). PD is the 
second most common neurodegenerative condition after 
Alzheimer’s Disease (Leroi, Collins, & Marsh, 2006).  In 
the United Kingdom  PD has a prevalence of 
approximately 27.4 per 10,000, which equates to around 
127,000 individuals (Parkinson’s UK, 2009). 
Individuals with PD are also impacted by the 
stigma/negative attitudes surrounding their condition 
(Ma, Saint-Hilaire, Thomas & Tickle-Degnen, 2016). 
Stigma can lead to a feeling of shame and 
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embarrassment, as a result of self-perceived 
inadequacy through loss of autonomy, visible symptoms 
and the experience of others’ attitudes and beliefs within 
the social context that surrounds the person with PD 
(Maffoni, Giardini, Pierobon, Ferrazzoli & Frazzitta, 
2017).  In addition, negative attitudes have 
consequences for individuals with stigmatising 
conditions, which may result in reduced social support, 
social exclusion and occupational loss (Goffman, 1963; 
Weiner, Perry & Magnusson, 1988). The felt sense of 
stigma can have detrimental effects on an individual’s 
self-esteem and contributes to reduced emotional 
wellbeing (Link & Phelan, 2001; Rao, Choi, Victorson, 
Bode, Peterman, Heinmann et al., 2009; Schrag, 
Jahanshahi, Quinn, 2001). 
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An individual’s perceived sense of control has also been 
shown to predict psychological outcomes in individuals 
with health conditions, including PD (see Hagger & 
Orbell, 2003; Garlovsky, Overton & Simpson, 2016). For 
individuals with PD, obtaining a sense of control in 
relation to their condition may not be possible given its 
degenerative nature. However, perceived control over 
other life domains may be more important (Eccles & 
Simpson, 2011).   
Thus, both perceptions of stigma and control have been 
shown to affect psychological outcomes for people with 
PD. However, currently the relationship between these 
psychological constructs is unclear. Results from a study 
with another degenerative condition (Alzheimer’s 
disease), found that negative social interactions which 
were marked by disempowerment, stigmatisation and 
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exclusion resulted in decreases in a sense of personal 
control (Harris & Sterin,1999). Consequently, the 
proposed study aims to assess whether perceived 
control mediates the association between perceived 
stigma and psychological outcomes for people with PD.  
The findings of the study will be used to inform clinical 
interventions with PD individuals. In addition, the results 
may help to influence the creation of campaigns to 
reduce stigma at a broader level.  
Individuals with PD will be asked to complete a number 
of validated measures. The data once collated will be 
statistically examined, with the intention of constructing 







This study will be powered to find a medium effect size for 
both the relationship between stigma and control and the 
relationship between control and wellbeing. At a power of .8 
and p<.05 approximately 70 participants will be needed 
(Fritz & MacKinnon, 2001) using a bias-corrected bootstrap 
for the model (Hayes, 2012).  
Inclusion criteria 
• Individuals who self-report a diagnosis of Parkinson’s 
disease will be eligible to take part in the project.  
• The survey will be written in English; thus, participants 
must have sufficient knowledge of written English to 
take part  
• Participants will be able to complete the research 




The study will be a cross-sectional survey using quantitative 
measures. The data will be quantitatively examined and a 
mediation analysis will be conducted using Hayes process 
tool (Hayes, 2012) to examine whether perceived control 
mediates the relationship between stigma and psychological 
distress and quality of life. 
The dependent variable will be scores of emotional 
wellbeing: the positive subscale of the Positive And 
Negative Affect Schedule (Watson, Clark & Tellegen, 1988), 
the Parkinson’s Disease Questionnaire (PDQ-8) Jenkinson 
et al., 2012) and the three components of the Depression 
Anxiety and Stress Scale (Lovibond & Lovibond, 1995) – 
see materials section for details on reliability and validity. 
The predictor variables will be perceived stigma, measured 
using the Stigma Scale for Chronic Illness (SSCI -24; 
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Molina, Choi, Cella & Rao, 2013) measured using and 
demographic and clinical variables (see below for more 
detail). 
The mediating variable will be measured by the Parkinson’s 
UK Scale of Perceived Control (PUKSoPC-15; Simpson, 
Chatzidamianos & Eccles, 2015) and the General Self-
Efficacy Scale (GSE-10; Jerusalem & Schwarzer, 1992)  
Materials 






• Work status 
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• Relationship status 
• Living arrangements (alone, co-habiting, 
residential/nursing home) 
Clinical Variables: 
• Age of onset 
• Time since diagnosis 
• Taking medication 
Validated Measures: 
• The Depression Anxiety and Stress Scale (DASS-21; 
Lovibond & Lovibond, 1995). This is a well-validated 
short-form version of the original scale (Henry & 
Crawford, 2005) and has been used with PD 
population (Dubrow-Marshall & Birtwell, 2016). The 
short-version is considered to be more acceptable to 
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individuals completing the measure (Henry & Crawford, 
2005). 
• The positive subscale of the Positive and Negative 
Affect Schedule (PANAS; Watson, Clark & Tellegen, 
1988) will be used to measure positive affect in PD in 
the last few weeks. The positive subscale alone will be 
used, as the in-depth evaluation of negative mood will 
be provided by the DASS-21. PANAS is a reliable and 
valid measure of assessing positive and negative affect 
in non-clinical populations (Crawford & Henry, 2004).  
• The Parkinson’s Disease Questionnaire (PDQ-8) will 
be used to measure quality of life (Jenkinson, 
Fitzpatrick, Peto, Dummett, Morley et al., 2012). 
• The Parkinson’s UK Scale of Perceived Control 
(PUKSoPC-15; Simpson, Chatzidamianos & Eccles, 
2015) will be administered. Parkinson’s UK members 
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helped in the development of this scale and it has been 
initially validated (Simpson et al., 2015).  
• Stigma Scale for Chronic Illness (SSCI-24; Molina, 
Choi, Cella & Rao, 2013) measures both perceived and 
enacted (carried out) stigma. The SSCI has been 
validated for use with individuals with neurological 
conditions, such as PD (Molina, Choi, Cella & Rao, 
2013).  
• The General Self-Efficacy Scale (GSE-10; Jerusalem 
& Schwarzer, 1992) will be used to assess individual’s 
general beliefs in their ability to respond and problem 
solve situations. The scale is a reliable and valid 
measure for use with individuals experiencing PD 





The project will be advertised through Parkinson’s UK 
website and on the Lancaster University DClinPsy 
webpage, to enable participants who are not members 
of Parkinson's UK but identify themselves as having PD, 
to participate. Participants will read information about the 
study and will be directed to the consent page. Once they 
have given their consent to take part in the research the 
online survey will appear (see appendices for measures 
attached). Should participants want to complete the survey 
in a paper format, contact details will appear in the 
information about the study detailing how they can access a 
hard copy. Paper copies of the information sheet and the 
consent form will be provided to individuals who wish to 
have information in this format. Once the consent form has 
been returned, a paper copy of the survey will be issued. At 
the end of the study, participants will be reminded of the 
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support resources given at the start of the survey. The 
survey should take approximately 30 minutes to complete. 
Participants’ data will be gathered electronically, and hard 
copy data will be inputted immediately into the electronic 
dataset. The hard copies of the questionnaires will be 
immediately destroyed.  
Proposed analysis 
The data will be statistically examined using a mediational 
regression model. Hayes process tool 
(http://www.processmacro.org/index.html), a bias-corrected 
bootstrap model, will be utilised to conduct the mediation 
regression.  
Practical issues 
For individuals who would prefer to access the survey in 
paper format, an additional cost of postage will be incurred. 




It is felt that participating in this study will not pose any 
significant risk to participants or researchers. There is a 
small risk that participants may become distressed when 
completing the survey. For this reason, participants will be 
informed prior to commencing the study that they can stop 
at any time during survey completion. However, due to the 
anonymity of participation, their data cannot be removed 
after they have agreed to take part. The participant 
information sheet will include sources of support and 
participants will be reminded of these at the end of the 
electronic survey. 
Service User involvement 
Parkinson’s UK Patient and Public Involvement group (PPI) 
members provided their feedback on the participant 
information sheet and consent form for the study. The 
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benefit for participants to take part was clarified and 
changes to wording in the documents were made based on 
their feedback to aid broad reader access.    
Timescale 
Ethical approval from Lancaster University Research Ethics 
Committee will be sought by the principal investigator in 
June 2017, with a view to the study commencing in 
September 2017.  
Once ethical approval has been granted, liaison with 
Parkinson’s UK will commence to enable the study to be 
approved by them and advertised via the charity’s website 
(expected September 2017).  
It is anticipated data collection will take place between 
September and December 2017 approximately 
Data will be analysed January – March 2018 
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The study will be written and submitted as part of a doctoral 
thesis to Lancaster University by May 2018.  
Appendices 
See attached documents for; 
Print screens of electronic participant information sheet and 
consent form 
Participant information Sheet – paper version 
Consent form – paper version 
Survey materials (demographic, clinical information and 
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1.3 Figure 1. Online Survey 





































































































































The Positive and Negative Affect Scale (PANAS)
 


























1.4 Figure 2. Approval Letter  
 
